



Universiteit
Leiden
The Netherlands

Maternal recognition of the (semi) allogeneic fetus during implantation and pregnancy

Lashley, Eileen Elisabeth Lynn O'Neill

Citation

Lashley, E. E. L. O. 'N. (2015, April 21). *Maternal recognition of the (semi) allogeneic fetus during implantation and pregnancy*. Retrieved from <https://hdl.handle.net/1887/32779>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/32779>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/32779> holds various files of this Leiden University dissertation

Author: Lashley, Eileen Elisabeth Lynn O'Neill

Title: Maternal recognition of the (semi) allogeneic fetus during implantation and pregnancy

Issue Date: 2015-04-21

Nederlandse Samenvatting


References

Curriculum Vitae

List of publications

Abbreviations

Acknowledgements



Nederlandse Samenvatting

1 Immunologische paradox

Tijdens de zwangerschap bestaat er een bijzondere immunologische situatie. De foetus heeft zowel maternale als paternale genen en is dus gedeeltelijk lichaamsvreemd voor de moeder, ook wel semi-allogeen genoemd. Gedurende de zwangerschap wordt een foetus echter getolereerd door het immuunsysteem van de moeder en niet afgestoten. Dit in tegenstelling tot een orgaantransplantatie, waarbij levenslange afweer-onderdrukkende medicatie en een uitvoerig zoektocht naar een geschikte donor noodzakelijk zijn om afstoting te voorkomen.

De bijzondere immunologische situatie tijdens zwangerschap wordt de 'immunologische paradox' genoemd en er zijn verschillende mechanismen geopperd die de maternale tolerantie zouden verklaren. Eén van de verklaringen is dat tijdens zwangerschap het afweersysteem onderdrukt is. Inmiddels weten we echter dat zowel de aangeboren als de verworven afweer actief zijn tijdens de zwangerschap en dat de herkenning van de moeder van haar ongeboren kind essentieel is voor het verloop van de zwangerschap.

Herkenning van lichaamseigen en lichaamsvreemd is een van de belangrijkste mechanismen van het afweersysteem om een specifieke afweerreactie te beginnen. Deze herkenning vindt plaats middels Humane Leukocyten Antigenen (HLA), moleculen welke op het membraan van alle cellen voorkomen. HLA kent een buitengewoon polymorfisme, wat wil zeggen dat er een grote individuele verscheidenheid bestaat. Specifieke afweercellen, T cellen, zijn in staat lichaamsvreemd MHC van bijvoorbeeld bacteriën te herkennen. Wat volgt is een immunologische reactie met als doel de vreemde cellen te verwijderen. Ook cellen van de foetus kunnen worden herkend als lichaamsvreemd en een afweerreactie uitlokken. Tijdens de zwangerschap blijken er echter allerlei aanpassingen van het maternale afweersysteem plaats te vinden waardoor een reactie tegen de foetus wordt onderdrukt, maar tegen andere indringers intact blijft. Niet of onvoldoende onderdrukking van de afweerreactie is mogelijk geassocieerd met een aantal zwangerschapscomplicaties, zoals herhaalde miskramen, zwangerschapsvergiftiging (pre-eclampsie) of verminderde vruchtbaarheid. In dit proefschrift bestuderen we daarom de immunologische herkenning en de afweerreactie van de moeder tijdens innesteling- en zwangerschapscomplicaties.

In dit proefschrift onderzoeken we bovendien de eiceldonatie zwangerschap. Zoals beschreven is tijdens een 'normale' zwangerschap de foetus gedeeltelijk lichaamsvreemd; na een eiceldonatie heeft het kind geen genen van de moeder en is het dus totaal allogeen. Immunologisch is deze situatie te vergelijken met een orgaantransplantatie waarbij ook een totaal lichaamsvreemd orgaan in het lichaam wordt gebracht. Kennis van immunologische

mechanismen verantwoordelijk voor een ongecompliceerde eiceldonatiezwangerschap zou gebruikt kunnen worden om een succesvolle orgaantransplantatie te bewerkstelligen. Aan de andere kant kan men een gecompliceerde eiceldonatiezwangerschap zien als een afstotingsreactie. Procedures die gevolgd worden om afstoting van een orgaan te minimaliseren, zoals selectie van een geschikte donor, zouden mogelijk voordelig effect hebben op het verloop van de zwangerschap na eiceldonatie.

2 Dit proefschrift

In **hoofdstuk 1** worden algemene aspecten van de immunologie met de betrokken afweercellen en eiwitten ingeleid. Tevens worden verschillende maternale en foetale mechanismen beschreven welke een rol spelen in de tolerantie tijdens zwangerschap en worden de zwangerschapscomplicaties welke in dit proefschrift zijn bestudeerd geïntroduceerd.

Verschillen in de specifieke afweerreactie tussen zwangere en niet-zwangere vrouwen werden onderzocht in **hoofdstuk 2**. In het bloed van deze vrouwen is gekeken naar percentages van diverse afweercellen zoals T cellen en B cellen. Daarnaast is onderzocht hoe de T cellen reageren wanneer ze lichaamsvreemd HLA herkennen middels een MLC (mixed lymphocyte culture) test. Hiervoor werden T cellen van de zwangere of niet-zwangere vrouw in een laboratorium setting samen gebracht met cellen van haar eigen kind, of met een vreemd kind. Wij vonden dat de mate waarin de T cellen vermenigvuldigen tijdens de herkenningfase gelijk is tussen zwangere en niet-zwangere vrouwen. Wel vonden we verschillen in de samenstelling van afweercellen en in de productie van cytokines, eiwitten betrokken bij de communicatie tussen afweercellen. Deze resultaten tonen dat zowel de aangeboren als de verworven afweer intensiever zijn tijdens de zwangerschap, maar dat dit niet leidt tot een andere afweerreactie wanneer gekeken wordt naar de proliferatie.

De afweerreactie die optreedt na herkenning van vreemd HLA kan cellulair of humoraal zijn. De humorale reactie wordt geïnitieerd door B cellen en leidt tot de productie van antistoffen tegen het vreemde antigen. Ook tijdens de zwangerschap worden er antistoffen gevormd. Wat de gevolgen zijn van deze antistoffen op het verloop van de zwangerschap, is echter niet bekend. In **hoofdstuk 3** hebben we een literatuurstudie en meta-analyse gedaan naar onderzoeken die de associatie tussen HLA antistoffen en zwangerschapscomplicaties onderzochten. De onderzoeken toonden echter een grote mate van klinische heterogeniteit, wat wil zeggen dat de geïnccludeerde patiënten en controle personen tussen de studie niet vergelijkbaar zijn. Vooralsnog kunnen we dus niet concluderen dat HLA antistoffen een (positief of negatief) effect hebben op de zwangerschap.

Zoals beschreven, is een kind na eiceldonatie totaal lichaamsvreemd ten opzichte van de moeder. In **hoofdstuk 4** is onderzocht of deze hogere mate van genetisch verschil invloed heeft op de productie van antistoffen gericht tegen het HLA van het kind. We vonden dat 69% van de vrouwen zwanger na eiceldonatie HLA antistoffen produceert, tegen 24-25% van de vrouwen zwanger na spontane conceptie of na IVF. De productie van antistoffen was positief gecorreleerd met het aantal HLA verschillen (mismatches) en epitooop verschillen. Ondanks de hoge mate van antistof productie waren alle eiceldonatie zwangerschappen geïnccludeerd in deze studie ongecompliceerd. We suggereren dat, in overeenstemming met andere literatuur, extra activatie van de T helper 2 (Th2) cel nodig is om deze zwangerschappen ongecompliceerd te houden.

De vraag is uiteraard, hoe de immuun activatie is in gecompliceerde eiceldonatie zwangerschap. Mogelijk speelt de onnatuurlijk hoge mate van HLA verschil een rol in het onderliggen mechanisme van complicaties in eiceldonatie zwangerschappen. In spontane zwangerschappen worden zwangerschapscomplicaties als preeclampsie en herhaalde miskramen echter geassocieerd met een laag HLA verschil en hoge mate van 'HLA sharing', een situatie die op kan treden in bijvoorbeeld inteelt populaties. Het onderliggend mechanisme verantwoordelijk voor de preeclampsie is dus mogelijk verschillend in eiceldonatie zwangerschappen. In **hoofdstuk 5** onderzochten we aspecten van de aangeboren afweer, de complement cascade, in vrouwen met preeclampsie zwanger na eiceldonatie, of na IVF met gebruik van eigen eicellen. Hoewel we in beide groepen een verhoogd percentage van placenta's met C4d depositie (marker van complement activatie) vonden, lijkt het mechanisme verantwoordelijk voor deze complement activatie te verschillen. In de groep vrouwen zwanger na eiceldonatie met preeclampsie kwamen namelijk geen groei vertraagde kinderen voor en werd geen op-regulatie van complement regulatoire eiwitten gevonden, eiwitten die de activatie van complement kunnen verminderen. Het lijkt dus dat de C4d depositie in eiceldonatie zwangerschappen gecompliceerd door preeclampsie meer specifiek is, veroorzaakt door schade in de placenta maar niet de schade veroorzakend.

In natuurlijke zwangerschappen lijkt er een selectie te zijn naar een optimaal aantal HLA matches en mismatches tussen moeder en foetus. In **hoofdstuk 6** vroegen wij ons af of er ook in ongecompliceerde eiceldonatiezwangerschappen een selectie is voor een bepaalde mate van HLA matching. Hiervoor berekenden we het bestaand aantal HLA matches en mismatches tussen moeder en foetus in eiceldonatie zwangerschappen met een ongerelateerde donor, en het aantal matches en mismatches als we de foetussen 'at random' zouden verdelen onder de moeders. We vonden meer gelijkenis tussen moeder en foetus dan bij een at random verdeling en deze gelijkenis was met name voor HLA klasse I. Mogelijk betekent dit dat selectie van een geschikte donor, met een optimaal aantal matches tussen donor en moeder, de uitkomst na eiceldonatie verbeterd. Hiervoor

is echter grootschalig onderzoek noodzakelijk, waarbij ook gecompliceerde eiceldonatie zwangerschappen worden onderzocht.

Voor het verloop van de zwangerschap is herkenning door het maternale afweersysteem van de foetus van belang voor het verloop van de zwangerschap. De situatie waarin er een weinig HLA verschil is tussen moeder en kind zou kunnen resulteren in weinig aanpassing van het maternale immuunsysteem tijdens de zwangerschap, wat mogelijk is geassocieerd met zwangerschapscomplicaties zoals herhaalde miskramen. Eerdere onderzoeken naar de invloed van HLA 'sharing' tussen partners en herhaalde miskramen lieten echter inconsistente resultaten zien. Reden voor deze inconsistentie zijn waarschijnlijk de verschillende definitie van herhaald miskramen en controle groepen en het gebruik van verschillende HLA typeringsmethoden. In **hoofdstuk 7** hebben we daarom alle onderzoeken vergeleken die gekeken hebben naar HLA allelen en HLA sharing in herhaald miskramen en die strikte inclusiecriteria handhaafden. We hadden echter te maken met hoge selectie en informatie bias en daardoor kunnen we, ondanks dat we in de meta-analyse vonden dat maternale dragerschap van bepaalde HLA allelen en sharing van bepaalde HLA antigenen een verhoogd risico gaven op herhaald miskramen, geen conclusies trekken.

In **hoofdstuk 8 en 9** richtten we ons op koppels met een verminderde vruchtbaarheid en herhaald implantatie falen. In **hoofdstuk 8** onderzochten we de naast de mate van HLA sharing, of er een verhoogde frequentie is voor een bepaalde groep van HLA-C in patiënten die *in vitro* fertilisatie hebben ondergaan maar ≥ 3 opeenvolgende mislukte terugplaatsingen hebben gehad. HLA-C komt voor op het celmembraan van placentacellen en gaat lokaal een interactie aan met maternale afweercellen. Eerder onderzoek heeft aangetoond dat een bepaalde combinatie tussen moederlijke NK cellen en HLA-C van de foetus nadelig kan zijn op het verloop van de zwangerschap. Wij vonden dat matернаal HLA-C2 geassocieerd was met implantatie falen. Tevens werd een genetische variant van HLA-G onderzocht, waarbij de invoeging van een extra stukje DNA (14 bp) nadelige effecten zou hebben op de vruchtbaarheid. Inderdaad vonden wij deze insertie vaker bij vrouwen met herhaaldelijk implantatie falen.

Tenslotte onderzochten we in **hoofdstuk 9** het percentage en de functie van T cellen in bloed van vrouwen die IVF hebben ondergaan vanwege onverklaarde infertiliteit en vrouwen die een spontane zwangerschap hebben doorgemaakt. We richtten ons met name op de rol van de 'regulatorische T cel', een afweercel die mogelijk belangrijk is om de maternale afweerreactie tegen de foetus te onderdrukken. Hiervoor onderzochten wij de vermenigvuldiging en cytokine productie van T cellen in een MLC, waarbij de cellen werden gestimuleerd met cellen van de eigen partner, of van een vreemde partner. Vervolgens herhaalden wij deze test met een fractie T cellen waar de regulatorische T cel uit

was verwijderd. We vonden dat T cellen van de IVF patiënten meer vermenigvuldigden na stimulatie, en dat een verminderde suppressieve capaciteit van de regulatoire T cel hier mogelijk verantwoordelijk voor is.

3 Conclusie

Tijdens de zwangerschap zijn alle onderdelen van het afweersysteem actief en wordt een foetus herkend als gedeeltelijk lichaamsvreemd. Het afweersysteem is echter aangepast om afstoting van de foetus te voorkomen. Onvoldoende aanpassing kan resulteren in een gecompliceerd verloop, of einde, van de zwangerschap en kennis van deze maladaptatie is van belang in het ontwikkelen van therapeutische en diagnostische mogelijkheden.

Zoals echter ook duidelijk wordt in dit proefschrift, is de aanpassing van het maternale immuunsysteem tijdens de zwangerschap complex en spelen verschillende genen, celtypen en eiwitten een rol. Daarnaast hebben ook andere factoren een belangrijke invloed, zoals milieufactoren, hormonen en epigenetica. Wij toonden aan dat genetische variaties (14 bp insertie in HLA-G) en regulatoire T cellen belangrijk zijn gedurende de implantatie en conceptie. Aanvullend onderzoek is echter noodzakelijk om de exacte bijdrage van deze factoren in de aanpassing van het maternale immuunsysteem tijdens zwangerschap te ontrafelen. Voor het doen van deze immunologische bepalingen, en bepalingen als screening naar HLA antistoffen of meten van HLA sharing tussen koppels, als diagnostiek bij vrouwen met bepaalde zwangerschapscomplicaties, bestaat vooralsnog onvoldoende bewijs en zal in de dagelijkse praktijk niet moeten worden aangeboden. Ook het aanbieden van bepaalde immunotherapie onder het mom van 'baat het niet dan schaadt het niet', blijkt echter weldegelijk meer schade aan te richten dan te helpen, en zou pas bij voldoende immunologisch bewijs kunnen worden gegeven. Hoewel dus steeds meer bekend wordt over het afweersysteem tijdens de zwangerschap zal verder onderzoek noodzakelijk zijn om de immunologische tolerantie naar de foetus te kunnen begrijpen.

Ook voor de bijzondere immunologische situatie die bestaat in eiceldonatie zwangerschappen geldt dat de gevonden resultaten verder zullen moeten worden onderzocht en ook in de gecompliceerde eiceldonatie zwangerschap, om meer inzicht te geven in het onderliggende mechanisme. Dit kan van belang zijn voor de toekomst van eiceldonatie, maar ook voor andere onderzoeksgebieden, zoals de transplantatie immunologie.

References

1. Medawar.: Some immunological and endocrinological problems raised by the evolution of viviparity in vertebrates. *Symp Soc Exp Biol* 44:320-338, 1953.
2. Ariga H, Ohto H, Busch MP, Imamura S, Watson R, Reed W, Lee TH: Kinetics of fetal cellular and cell-free DNA in the maternal circulation during and after pregnancy: implications for noninvasive prenatal diagnosis. *Transfusion* 41:1524-1530, 2001.
3. Hunt J.S., Petroff M.G., McIntire R.H., Ober C.: HLA-G and immune tolerance in pregnancy. *The FASEB journal* 19:681-693, 2005.
4. Head JR, Drake BL, Zuckermann FA: Major histocompatibility antigens on trophoblast and their regulation: implications in the maternal-fetal relationship. *Am J Reprod Immunol Microbiol* 15:12-18, 1987.
5. Luppi P: How immune mechanisms are affected by pregnancy. *Vaccine* 21:3352-3357, 2003.
6. Parham P: *The immune system.*, Garland Science, 2009.
7. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, Yokoyama WM, Ugolini S: Innate or adaptive immunity? The example of natural killer cells. *Science* 331:44-49, 2011.
8. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B, Palucka K: Immunobiology of dendritic cells. *Annu Rev Immunol* 18:767-811, 2000.
9. Davis MM, Kim SK, Hood L: Immunoglobulin class switching: developmentally regulated DNA rearrangements during differentiation. *Cell* 22:1-2, 1980.
10. Slifka MK, Ahmed R: Long-lived plasma cells: a mechanism for maintaining persistent antibody production. *Curr Opin Immunol* 10:252-258, 1998.
11. Saito S, Shiozaki A, Sasaki Y, Nakashima A, Shima T, Ito M: Regulatory T cells and regulatory natural killer (NK) cells play important roles in feto-maternal tolerance. *Semin Immunopathol* 29:115-122, 2007.
12. Strom TB, Koulmanda M: Recently discovered T cell subsets cannot keep their commitments. *J Am Soc Nephrol* 20:1677-1680, 2009.
13. Hanidziar D, Koulmanda M: Inflammation and the balance of Treg and Th17 cells in transplant rejection and tolerance. *Curr Opin Organ Transplant* 15:411-415, 2010.
14. Saito S, Sakai M: Th1/Th2 balance in preeclampsia. *J Reprod Immunol* 59:161-173, 2003.
15. Korn T, Oukka M, Kuchroo V, Bettelli E: Th17 cells: effector T cells with inflammatory properties. *Semin Immunol* 19:362-371, 2007.
16. O'Garra A, Vieira P: Regulatory T cells and mechanisms of immune system control. *Nat Med* 10:801-805, 2004.
17. Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki S, Sakihama T, Itoh M, Kuniyasu Y, Nomura T, Toda M, Takahashi T: Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. *Immunol Rev* 182:18-32, 2001.
18. Fontenot JD, Gavin MA, Rudensky AY: Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. *Nat Immunol* 4:330-336, 2003.
19. Khattry R, Cox T, Yasayko SA, Ramsdell F: An essential role for Scurfin in CD4+CD25+ T regulatory cells. *Nat Immunol* 4:337-342, 2003.
20. Guerin LR, Prins JR, Robertson SA: Regulatory T-cells and immune tolerance in pregnancy: a new target for infertility treatment? *Hum Reprod Update* 15:517-535, 2009.
21. Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, Gottlieb PA, Kapranov P, Gingeras TR, Fazekas de St GB, Clayberger C, Soper DM, Ziegler SF, Bluestone JA: CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. *J Exp Med* 203:1701-1711, 2006.
22. Tilburgs T, Schonkeren D, Eikmans M, Nagtzaam NM, Datema G, Swings GM, Prins F, van Lith JM, van der Mast BJ, Roelen DL, Scherjon SA, Claas FH: Human decidual tissue contains

- differentiated CD8+ effector-memory T cells with unique properties. *J Immunol* 185:4470-4477, 2010.
23. Pipkin ME, Lieberman J: Delivering the kiss of death: progress on understanding how perforin works. *Curr Opin Immunol* 19:301-308, 2007.
24. Bratke K, Kuepper M, Bade B, Virchow JC, Jr., Luttmann W: Differential expression of human granzymes A, B, and K in natural killer cells and during CD8+ T cell differentiation in peripheral blood. *Eur J Immunol* 35:2608-2616, 2005.
25. van Lier RA, ten Berge IJ, Gamadia LE: Human CD8(+) T-cell differentiation in response to viruses. *Nat Rev Immunol* 3:931-939, 2003.
26. Chang CC, Ciubotariu R, Manavalan JS, Yuan J, Colovai AI, Piazza F, Lederman S, Colonna M, Cortesini R, Dalla-Favera R, Suciuc-Foca N: Tolerization of dendritic cells by T(S) cells: the crucial role of inhibitory receptors ILT3 and ILT4. *Nat Immunol* 3:237-243, 2002.
27. Mehra NK, Kaur G: MHC-based vaccination approaches: progress and perspectives. *Expert Rev Mol Med* 5:1-17, 2003.
28. Roitt, Brostoff, Male: *Immunology*. 2006.
29. Siegel JP, Sharon M, Smith PL, Leonard WJ: The IL-2 receptor beta chain (p70): role in mediating signals for LAK, NK, and proliferative activities. *Science* 238:75-78, 1987.
30. Lenardo M, Chan KM, Hornung F, McFarland H, Siegel R, Wang J, Zheng L: Mature T lymphocyte apoptosis—immune regulation in a dynamic and unpredictable antigenic environment. *Annu Rev Immunol* 17:221-253, 1999.
31. Malek TR, Castro I: Interleukin-2 receptor signaling: at the interface between tolerance and immunity. *Immunity* 33:153-165, 2010.
32. Rochman Y, Spolski R, Leonard WJ: New insights into the regulation of T cells by gamma(c) family cytokines. *Nat Rev Immunol* 9:480-490, 2009.
33. Saito S, Umekage H, Sakamoto Y, Sakai M, Tanebe K, Sasaki Y, Morikawa H: Increased T-helper-1-type immunity and decreased T-helper-2-type immunity in patients with preeclampsia. *Am J Reprod Immunol* 41:297-306, 1999.
34. Bowen JM, Chamley L, Mitchell MD, Keelan JA: Cytokines of the placenta and extra-placental membranes: biosynthesis, secretion and roles in establishment of pregnancy in women. *Placenta* 23:239-256, 2002.
35. Prins JR, Gomez-Lopez N, Robertson SA: Interleukin-6 in pregnancy and gestational disorders. *J Reprod Immunol* 95:1-14, 2012.
36. Scherjon S.A., Claas FH: *Immunology at the maternal-fetal interface*. In Kurjak A, Chervenak FA. (eds): *Textbook of Perinatal Medicine*., Informa UK Ltd, 2006.
37. Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, Wang Y, Hood L, Zhu Z, Tian Q, Dong C: A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. *Nat Immunol* 6:1133-1141, 2005.
38. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, Weaver CT: Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. *Nat Immunol* 6:1123-1132, 2005.
39. Wang WJ, Hao CF, Yi L, Yin GJ, Bao SH, Qiu LH, Lin QD: Increased prevalence of T helper 17 (Th17) cells in peripheral blood and decidua in unexplained recurrent spontaneous abortion patients. *J Reprod Immunol* 84:164-170, 2010.
40. Jones RL, Stoikos C, Findlay JK, Salamonsen LA: TGF-beta superfamily expression and actions in the endometrium and placenta. *Reproduction* 132:217-232, 2006.
41. Chaouat G, Dubanchet S, Ledee N: Cytokines: Important for implantation? *J Assist Reprod Genet* 24:491-505, 2007.
42. Munoz-Suano A, Hamilton AB, Betz AG: Gimme shelter: the immune system during pregnancy. *Immunol Rev* 241:20-38, 2011.
43. The menstrual cycle. In Linda J.Heffner, Danny J.Schust (eds): *The reproductive system at a glance*., Blackwell Publishing, 2010.

44. Harper MJ: The implantation window. *Baillieres Clin Obstet Gynaecol* 6:351-371, 1992.
45. Bulmer JN, Morrison L, Longfellow M, Ritson A, Pace D: Granulated lymphocytes in human endometrium: histochemical and immunohistochemical studies. *Hum Reprod* 6:791-798, 1991.
46. Arruvito L, Sanz M, Banham AH, Fainboim L: Expansion of CD4+CD25+and FOXP3+ regulatory T cells during the follicular phase of the menstrual cycle: implications for human reproduction. *J Immunol* 178:2572-2578, 2007.
47. Vince GS, Starkey PM, Jackson MC, Sargent IL, Redman CW: Flow cytometric characterisation of cell populations in human pregnancy decidua and isolation of decidual macrophages. *J Immunol Methods* 132:181-189, 1990.
48. Larsen WJ: Gametogenesis, fertilization and the first week. In Sherman LS, Potter SS, Scott WJ (eds): *Human Embryology*. New York, Churchill Livingstone, 2001.
49. Hunt J.S., Langat D.K., McIntire R.H., Morales P.J.: The role of HLA-G in human pregnancy. *Reproductive biology and endocrinology* 4 (suppl):S1-S10, 2006.
50. Moffett A., King: Natural killer cells and pregnancy. *Nature review immunology* 2:656-663, 2002.
51. Burton GB, Jauniaux E: Early placental development and pregnancy outcome. In Macklon NS, Greer IA, Steegers EAP (eds): *Textbook of periconceptional medicine*. London, Informa Healthcare, 2009.
52. Moffett A, Loke C: Immunology of placentation in eutherian mammals. *Nat Rev Immunol* 6:584-594, 2006.
53. Solier C, Aguerre-Girr M, Lenfant F, Campan A, Berrebi A, Rebmann V, Grosse-Wilde H, Le BP: Secretion of pro-apoptotic intron 4-retaining soluble HLA-G1 by human villous trophoblast. *Eur J Immunol* 32:3576-3586, 2002.
54. Le Bouteiller P., Orr H.T.: HLA-G and pregnancy. *Reviews of reproduction* 2:7-13, 1997.
55. Blaschitz A., Hutter H, Dohr G.: HLA Class I protein expression in the human placenta. *Early Pregnancy* 5:67-69, 2001.
56. Hunt J.S., Pace J.L., Morales P.J., Ober C.: Immunogenicity of the soluble isoforms of HLA-G. *Molecular Human Reproduction* 9:729-735, 2003.
57. Le BP, Pizzato N, Barakonyi A, Solier C: HLA-G, pre-eclampsia, immunity and vascular events. *J Reprod Immunol* 59:219-234, 2003.
58. Naji A, Durrbach A, Carosella ED, Rouas-Freiss N: Soluble HLA-G and HLA-G1 expressing antigen-presenting cells inhibit T-cell alloproliferation through ILT-2/ILT-4/FasL-mediated pathways. *Hum Immunol* 68:233-239, 2007.
59. Moffett A., Loke C.: Implantation, Embryo-maternal interactions, immunology and modulation of the uterine environment- A workshop report. *Placenta* 27 Suppl A:S4-S5, 2006.
60. King A., Hiby S.E., Gardner L., Joseph S., Bowen J.M., Verma S., Burrows T.D., Loke Y.W.: Recognition of trophoblast HLA Class I molecules by decidual NK cell receptor- a review. *Placenta* 21 Supp A:s81-s85, 2000.
61. Sargent I.L., Borzychowski A.M., Redman C.W.G.: NK cells and pre-eclampsia. *Journal of reproductive immunology* 76:40-44, 2007.
62. Lila N, Rouas-Freiss N, Dausset J, Carpentier A, Carosella ED: Soluble HLA-G protein secreted by allo-specific CD4+ T cells suppresses the allo-proliferative response: a CD4+ T cell regulatory mechanism. *Proc Natl Acad Sci U S A* 98:12150-12155, 2001.
63. Kapasi K, Albert SE, Yie S, Zavazava N, Librach CL: HLA-G has a concentration-dependent effect on the generation of an allo-CTL response. *Immunology* 101:191-200, 2000.
64. Rebmann V, van d, V, Passler M, Pfeiffer K, Krebs D, Grosse-Wilde H: Association of soluble HLA-G plasma levels with HLA-G alleles. *Tissue Antigens* 57:15-21, 2001.
65. Hviid TV, Hylenius S, Rorbye C, Nielsen LG: HLA-G allelic variants are associated with differences in the HLA-G mRNA isoform profile and HLA-G mRNA levels. *Immunogenetics* 55:63-79, 2003.

66. Rizzo R, Hviid TV, Govoni M, Padovan M, Rubini M, Melchiorri L, Stignani M, Carturan S, Grappa MT, Fotinidi M, Ferretti S, Voss A, Laustrop H, Junker P, Trotta F, Baricordi OR: HLA-G genotype and HLA-G expression in systemic lupus erythematosus: HLA-G as a putative susceptibility gene in systemic lupus erythematosus. *Tissue Antigens* 71:520-529, 2008.
67. Hviid TV, Rizzo R, Melchiorri L, Stignani M, Baricordi OR: Polymorphism in the 5' upstream regulatory and 3' untranslated regions of the HLA-G gene in relation to soluble HLA-G and IL-10 expression. *Hum Immunol* 67:53-62, 2006.
68. Hunt JS, Morales PJ, Pace JL, Fazleabas AT, Langat DK: A commentary on gestational programming and functions of HLA-G in pregnancy. *Placenta* 28 Suppl A:S57-S63, 2007.
69. Tilburgs T, van der Mast BJ, Nagtzaam NM, Roelen DL, Scherjon SA, Claas FH: Expression of NK cell receptors on decidual T cells in human pregnancy. *J Reprod Immunol* 80:22-32, 2009.
70. Tilburgs T, Scherjon SA, van der Mast BJ, Haasnoot GW, Versteeg V, Roelen DL, van Rood JJ, Claas FH: Fetal-maternal HLA-C mismatch is associated with decidual T cell activation and induction of functional T regulatory cells. *J Reprod Immunol* 82:148-157, 2009.
71. Moffett A, Hiby S.E.: How does the maternal immune system contribute to the development of pre-eclampsia? *Placenta* 21 suppl A:S51-S56, 2007.
72. Hiby SE, Walker JJ, O'shaughnessy KM, Redman CW, Carrington M, Trowsdale J, Moffett A: Combinations of maternal KIR and fetal HLA-C genes influence the risk of preeclampsia and reproductive success. *J Exp Med* 200:957-965, 2004.
73. Hiby SE, Regan L, Lo W, Farrell L, Carrington M, Moffett A: Association of maternal killer-cell immunoglobulin-like receptors and parental HLA-C genotypes with recurrent miscarriage. *Hum Reprod* 23:972-976, 2008.
74. Flores AC, Marcos CY, Paladino N, Arruvito L, Williams F, Middleton D, Fainboim L: KIR receptors and HLA-C in the maintenance of pregnancy. *Tissue Antigens* 69 Suppl 1:112-113, 2007.
75. Witt CS, Goodridge J, Gerbase-Delima MG, Daher S, Christiansen FT: Maternal KIR repertoire is not associated with recurrent spontaneous abortion. *Hum Reprod* 19:2653-2657, 2004.
76. Sindram-Trujillo A.P., Scherjon S.A., van Hulst-van Miert P.P.: Differential distribution of NK cells in decidua basalis compared with decidua parietalis after uncomplicated human term pregnancy. *Human Immunology* 64:921-929, 2003.
77. Repnik U., Tilburgs T, Roelen D.L.: Comparison of macrophage phenotype between decidua basalis and decidua parietalis by flow cytometry. *Placenta* 29:405-412, 2008.
78. Tilburgs T, Roelen D.L., van der Mast B.J.: Differential distribution of CD24+/CD25bright and CD8+/CD28- T-cells in decidua and maternal blood during human pregnancy. *Placenta* 27 suppl A:S47-S53, 2006.
79. Tilburgs T, Roelen D.L., van der Mast B.J.: Evidence for a selective migration of fetus-specific CD4+/CD25bright regulatory T cells from the peripheral blood to the human pregnancy. *Journal of Immunology* 180:5737-5745, 2008.
80. Gomez-Lopez N, Guilbert LJ, Olson DM: Invasion of the leukocytes into the fetal-maternal interface during pregnancy. *J Leukoc Biol* 88:625-633, 2010.
81. Lash GE, Robson SC, Bulmer JN: Review: Functional role of uterine natural killer (uNK) cells in human early pregnancy decidua. *Placenta* 31 Suppl:S87-S92, 2010.
82. Thomson AJ, Telfer JF, Young A, Campbell S, Stewart CJ, Cameron IT, Greer IA, Norman JE: Leukocytes infiltrate the myometrium during human parturition: further evidence that labour is an inflammatory process. *Hum Reprod* 14:229-236, 1999.
83. Jacobs R, Hintzen G, Kemper A, Beul K, Kempf S, Behrens G, Sykora KW, Schmidt RE: CD56bright cells differ in their KIR repertoire and cytotoxic features from CD56dim NK cells. *Eur J Immunol* 31:3121-3127, 2001.
84. Hanna J, Goldman-Wohl D, Hamani Y, Avraham I, Greenfield C, Natanson-Yaron S, Prus D, Cohen-Daniel L, Arnon TI, Manaster I, Gazit R, Yutkin V, Benharroch D, Porgador A, Keshet E, Yagel S, Mandelboim O: Decidual NK cells regulate key developmental processes at the human fetal-maternal interface. *Nat Med* 12:1065-1074, 2006.

85. Hiby S.E., Walker J.J., O'Shaughnessy K.M., Redman C.W.G., Carrington M., Trowsdale J., Moffett A.: Combinations of maternal KIR and fetal HLA-C genes influence the risk of preeclampsia and reproductive success. *The Journal of experimental medicine* 200:957-965, 4 A.D.
86. Hiby S.E., Regan L., Lo W., Farrell L., Carrington M., Moffett A.: Association of maternal killer-cell immunoglobulin-like receptors and parental HLA-C genotypes with recurrent miscarriage. *Human Reproduction* 23:972-976, 2008.
87. Verma S, King A, Loke YW: Expression of killer cell inhibitory receptors on human uterine natural killer cells. *Eur J Immunol* 27:979-983, 1997.
88. Wegmann TG, Lin H, Guilbert L, Mosmann TR: Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a Th2 phenomenon? *Immunol Today* 14:353-356, 1993.
89. Piccinni MP, Beloni L, Livi C, Maggi E, Scarselli G, Romagnani S: Defective production of both leukemia inhibitory factor and type 2 T-helper cytokines by decidual T cells in unexplained recurrent abortions. *Nat Med* 4:1020-1024, 1998.
90. Raghupathy R: Th1-type immunity is incompatible with successful pregnancy. *Immunol Today* 18:478-482, 1997.
91. Saito S, Tsukaguchi N, Hasegawa T, Michimata T, Tsuda H, Narita N: Distribution of Th1, Th2, and Th0 and the Th1/Th2 cell ratios in human peripheral and endometrial T cells. *Am J Reprod Immunol* 42:240-245, 1999.
92. Chaouat G, Ledee-bataille N, Dubanchet S, Zourbas S, Sandra O, Martal J: TH1/TH2 paradigm in pregnancy: paradigm lost? Cytokines in pregnancy/early abortion: reexamining the TH1/TH2 paradigm. *Int Arch Allergy Immunol* 134:93-119, 2004.
93. Chaouat G: The Th1/Th2 paradigm: still important in pregnancy? *Semin Immunopathol* 29:95-113, 2007.
94. Svensson L, Arvola M, Sallstrom MA, Holmdahl R, Mattsson R: The Th2 cytokines IL-4 and IL-10 are not crucial for the completion of allogeneic pregnancy in mice. *J Reprod Immunol* 51:3-7, 2001.
95. Aluvihare VR, Kallikourdis M, Betz AG: Regulatory T cells mediate maternal tolerance to the fetus. *Nat Immunol* 5:266-271, 2004.
96. Zenclussen AC, Gerlof K, Zenclussen ML, Sollwedel A, Bertoja AZ, Ritter T, Kotsch K, Leber J, Volk HD: Abnormal T-cell reactivity against paternal antigens in spontaneous abortion: adoptive transfer of pregnancy-induced CD4+CD25+ T regulatory cells prevents fetal rejection in a murine abortion model. *Am J Pathol* 166:811-822, 2005.
97. Zenclussen AC, Gerlof K, Zenclussen ML, Ritschel S, Zambon BA, Fest S, Hontsu S, Ueha S, Matsushima K, Leber J, Volk HD: Regulatory T cells induce a privileged tolerant microenvironment at the fetal-maternal interface. *Eur J Immunol* 36:82-94, 2006.
98. Jin LP, Zhou YH, Zhu XY, Wang MY, Li DJ: Adoptive transfer of paternal antigen-hyporesponsive T cells facilitates a Th2 bias in peripheral lymphocytes and at materno-fetal interface in murine abortion-prone matings. *Am J Reprod Immunol* 56:258-266, 2006.
99. Yang H, Qiu L, Chen G, Ye Z, Lu C, Lin Q: Proportional change of CD4+CD25+ regulatory T cells in decidua and peripheral blood in unexplained recurrent spontaneous abortion patients. *Fertil Steril* 89:656-661, 2008.
100. Sasaki Y, rmochwal-Kolarz D, Suzuki D, Sakai M, Ito M, Shima T, Shiozaki A, Rolinski J, Saito S: Proportion of peripheral blood and decidual CD4(+) CD25(bright) regulatory T cells in pre-eclampsia. *Clin Exp Immunol* 149:139-145, 2007.
101. Saito S, Nakashima A, Shima T, Ito M: Th1/Th2/Th17 and regulatory T-cell paradigm in pregnancy. *Am J Reprod Immunol* 2010.
102. Gustafsson C, Mjosberg J, Matussek A, Geffers R, Matthiesen L, Berg G, Sharma S, Buer J, Ernerudh J: Gene expression profiling of human decidual macrophages: evidence for immunosuppressive phenotype. *PLoS One* 3:e2078, 2008.
103. Heikkinen J, Mottonen M, Komi J, Alanen A, Lassila O: Phenotypic characterization of human decidual macrophages. *Clin Exp Immunol* 131:498-505, 2003.

104. Mellor AL, Munn DH: IDO expression by dendritic cells: tolerance and tryptophan catabolism. *Nat Rev Immunol* 4:762-774, 2004.
105. Girardi G, Prohaszka Z, Bulla R, Tedesco F, Scherjon S: Complement activation in animal and human pregnancies as a model for immunological recognition. *Mol Immunol* 48:1621-1630, 2011.
106. Wasowska BA, Lee CY, Halushka MK, Baldwin WM, III: New concepts of complement in allorecognition and graft rejection. *Cell Immunol* 248:18-30, 2007.
107. Girardi G: Complement inhibition keeps mothers calm and avoids fetal rejection. *Immunol Invest* 37:645-659, 2008.
108. Guller S, LaChapelle L: The role of placental Fas ligand in maintaining immune privilege at maternal-fetal interfaces. *Semin Reprod Endocrinol* 17:39-44, 1999.
109. Hammer A, Blaschitz A, Daxböck C, Walcher W, Dohr G: Fas and Fas-ligand are expressed in the uteroplacental unit of first-trimester pregnancy. *Am J Reprod Immunol* 41:41-51, 1999.
110. Chaouat G, Clark DA: FAS/FAS ligand interaction at the placental interface is not required for the success of allogeneic pregnancy in anti-paternal MHC preimmunized mice. *Am J Reprod Immunol* 45:108-115, 2001.
111. Moffett A., Regan L., Braude P.: Natural killer cells, miscarriage, and infertility. *BMJ* 329:1283-1285, 2004.
112. van der Hoorn ML, Scherjon SA, Claas FH: Egg donation pregnancy as an immunological model for solid organ transplantation. *Transpl Immunol* 25:89-95, 2011.
113. Macklon NS, Geraedts JP, Fauser BC: Conception to ongoing pregnancy: the 'black box' of early pregnancy loss. *Hum Reprod Update* 8:333-343, 2002.
114. Boomsma CM, Kavelaars A, Eijkemans MJ, Lentjes EG, Fauser BC, Heijnen CJ, Macklon NS: Endometrial secretion analysis identifies a cytokine profile predictive of pregnancy in IVF. *Hum Reprod* 24:1427-1435, 2009.
115. Andersen AN, Gianaroli L, Felberbaum R, de MJ, Nygren KG: Assisted reproductive technology in Europe, 2001. Results generated from European registers by ESHRE. *Hum Reprod* 20:1158-1176, 2005.
116. Laufer N, Simon A: Recurrent implantation failure: current update and clinical approach to an ongoing challenge. *Fertil Steril* 97:1019-1020, 2012.
117. Rinehart J: Recurrent implantation failure: definition. *J Assist Reprod Genet* 24:284-287, 2007.
118. Thornhill AR, Die-Smulders CE, Geraedts JP, Harper JC, Harton GL, Lavery SA, Moutou C, Robinson MD, Schmutzler AG, Scriven PN, Sermon KD, Wilton L: ESHRE PGD Consortium 'Best practice guidelines for clinical preimplantation genetic diagnosis (PGD) and preimplantation genetic screening (PGS)'. *Hum Reprod* 20:35-48, 2005.
119. Rai R, Regan L: Recurrent miscarriage. *Lancet* 368:601-611, 2006.
120. Branch DW, Gibson M, Silver RM: Clinical practice. Recurrent miscarriage. *N Engl J Med* 363:1740-1747, 2010.
121. Rai R, Regan L: Recurrent miscarriage. *Lancet* 368:601-611, 2006.
122. Pandey MK, Rani R, Agrawal S: An update in recurrent spontaneous abortion. *Arch Gynecol Obstet* 272:95-108, 2005.
123. Wilczynski JR: Immunological analogy between allograft rejection, recurrent abortion and pre-eclampsia - the same basic mechanism? *Hum Immunol* 67:492-511, 2006.
124. Khong TY: The pathology of placenta accreta, a worldwide epidemic. *J Clin Pathol* 61:1243-1246, 2008.
125. Saftlas AF, Olson DR, Franks AL, Atrash HK, Pokras R: Epidemiology of preeclampsia and eclampsia in the United States, 1979-1986. *Am J Obstet Gynecol* 163:460-465, 1990.
126. Khan KS, Wojdyla D, Say L, Gulmezoglu AM, Van Look PF: WHO analysis of causes of maternal death: a systematic review. *Lancet* 367:1066-1074, 2006.

127. Steegers EA, von DP, Duvekot JJ, Pijnenborg R: Pre-eclampsia. *Lancet* 376:631-644, 2010.
128. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. American College of Obstetricians and Gynecologists. *Int J Gynaecol Obstet* 77:67-75, 2002.
129. Young BC, Levine RJ, Karumanchi SA: Pathogenesis of preeclampsia. *Annu Rev Pathol* 5:173-192, 2010.
130. Duckitt K, Harrington D: Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. *BMJ* 330:565, 2005.
131. Bellamy L, Casas JP, Hingorani AD, Williams DJ: Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. *BMJ* 335:974, 2007.
132. Sargent I.L., Borzychowski A.M., Redman C.W.G.: Immunoregulation in normal pregnancy and pre-eclampsia: an overview. *Reprod Biomed Online* 13:680-686, 2006.
133. Roberts JM, Bell MJ: If we know so much about preeclampsia, why haven't we cured the disease? *J Reprod Immunol* 2013.
134. Raymond D, Peterson E: A critical review of early-onset and late-onset preeclampsia. *Obstet Gynecol Surv* 66:497-506, 2011.
135. Klonoff-Cohen HS, Savitz DA, Cefalo RC, McCann MF: An epidemiologic study of contraception and preeclampsia. *JAMA* 262:3143-3147, 1989.
136. Robillard PY, Hulsey TC: Association of pregnancy-induced-hypertension, pre-eclampsia, and eclampsia with duration of sexual cohabitation before conception. *Lancet* 347:619, 1996.
137. Dekker GA, Robillard PY, Hulsey TC: Immune maladaptation in the etiology of preeclampsia: a review of corroborative epidemiologic studies. *Obstet Gynecol Surv* 53:377-382, 1998.
138. Kyrrou D, Kolibianakis EM, Devroey P, Fatemi HM: Is the use of donor sperm associated with a higher incidence of preeclampsia in women who achieve pregnancy after intrauterine insemination? *Fertil Steril* 93:1124-1127, 2010.
139. Smith GN, Walker M, Tessier JL, Millar KG: Increased incidence of preeclampsia in women conceiving by intrauterine insemination with donor versus partner sperm for treatment of primary infertility. *Am J Obstet Gynecol* 177:455-458, 1997.
140. Wang JX, Knottnerus AM, Schuit G, Norman RJ, Chan A, Dekker GA: Surgically obtained sperm, and risk of gestational hypertension and pre-eclampsia. *Lancet* 359:673-674, 2002.
141. Trounson A, Leeton J, Besanko M, Wood C, Conti A: Pregnancy established in an infertile patient after transfer of a donated embryo fertilised in vitro. *Br Med J (Clin Res Ed)* 286:835-838, 1983.
142. Lutjen P, Trounson A, Leeton J, Findlay J, Wood C, Renou P: The establishment and maintenance of pregnancy using in vitro fertilization and embryo donation in a patient with primary ovarian failure. *Nature* 307:174-175, 1984.
143. Bustillo M, Buster JE, Cohen SW, Thorneycroft IH, Simon JA, Boyers SP, Marshall JR, Seed RW, Louw JA, Seed RG: Nonsurgical ovum transfer as a treatment in infertile women. Preliminary experience. *JAMA* 251:1171-1173, 1984.
144. Antinori S, Versaci C, Gholami GH, Panci C, Caffa B: Oocyte donation in menopausal women. *Hum Reprod* 8:1487-1490, 1993.
145. Klein J, Sauer MV: Oocyte donation. *Best Pract Res Clin Obstet Gynaecol* 16:277-291, 2002.
146. Pados G, Camus M, Van SA, Bonduelle M, Devroey P: The evolution and outcome of pregnancies from oocyte donation. *Hum Reprod* 9:538-542, 1994.
147. Ferraretti AP, Goossens V, Kupka M, Bhattacharya S, de MJ, Castilla JA, Erb K, Korsak V, Nyboe AA: Assisted reproductive technology in Europe, 2009: results generated from European registers by ESHRE. *Hum Reprod* 2013.
148. Janssens PM, Simons AH, van Kooij RJ, Blokzijl E, Dunselman GA: A new Dutch Law regulating provision of identifying information of donors to offspring: background, content and impact. *Hum Reprod* 21:852-856, 2006.

149. Meer-Noort I, Kremer J.A.M., Alberda A.Th., Verhoeff A., van Hooff M.H.A.: Cross border reproductive care; gebruik van eiceldonatie in het buitenland door Nederlandse vrouwen. NTOG 98: 2011.
150. The Practice Committee of the American Society for Reproductive Medicine: Use of clomiphene citrate in women. *Fertil Steril* 82 Suppl 1:S90-S96, 2004.
151. Paulson RJ, Hatch IE, Lobo RA, Sauer MV: Cumulative conception and live birth rates after oocyte donation: implications regarding endometrial receptivity. *Hum Reprod* 12:835-839, 1997.
152. van Loendersloot LL, van WM, Limpens J, Bossuyt PM, Repping S, van d, V: Predictive factors in in vitro fertilization (IVF): a systematic review and meta-analysis. *Hum Reprod Update* 16:577-589, 2010.
153. Cohen MA, Lindheim SR, Sauer MV: Donor age is paramount to success in oocyte donation. *Hum Reprod* 14:2755-2758, 1999.
154. Soares SR, Troncoso C, Bosch E, Serra V, Simon C, Remohi J, Pellicer A: Age and uterine receptiveness: predicting the outcome of oocyte donation cycles. *J Clin Endocrinol Metab* 90:4399-4404, 2005.
155. Navot D, Drews MR, Bergh PA, Guzman I, Karstaedt A, Scott RT, Jr., Garrisi GJ, Hofmann GE: Age-related decline in female fertility is not due to diminished capacity of the uterus to sustain embryo implantation. *Fertil Steril* 61:97-101, 1994.
156. van der Hoorn ML, Lashley EE, Bianchi DW, Claas FH, Schonkeren CM, Scherjon SA: Clinical and immunologic aspects of egg donation pregnancies: a systematic review. *Hum Reprod Update* 16:704-712, 2010.
157. Abdalla HI, Billett A, Kan AK, Baig S, Wren M, Korea L, Studd JW: Obstetric outcome in 232 ovum donation pregnancies. *Br J Obstet Gynaecol* 105:332-337, 1998.
158. Blanchette H: Obstetric performance of patients after oocyte donation. *Am J Obstet Gynecol* 168:1803-1807, 1993.
159. Sheffer-Mimouni G, Mashlach S, Dor J, Levran D, Seidman DS: Factors influencing the obstetric and perinatal outcome after oocyte donation. *Hum Reprod* 17:2636-2640, 2002.
160. Soderstrom-Anttila V, Tiitinen A, Foudila T, Hovatta O: Obstetric and perinatal outcome after oocyte donation: comparison with in-vitro fertilization pregnancies. *Hum Reprod* 13:483-490, 1998.
161. Yaron Y, Ochshorn Y, Amit A, Kogosowski A, Yovel I, Lessing JB: Oocyte donation in Israel: a study of 1001 initiated treatment cycles. *Hum Reprod* 13:1819-1824, 1998.
162. Kim HS, Yang KM, Cha SH, Song IO, Kang IS: Obstetric outcomes after oocyte donation in patients with premature ovarian failure. Abstracts of the 21st annual meeting of the ESHRE, Copenhagen, Denmark 2005. 20[Suppl 1], i34.
163. Lashley LE, van der Hoorn ML, Scherjon SA: [Pre-eclampsia as a complication of egg donation: a different pathophysiological mechanism?]. *Ned Tijdschr Geneesk* 154:A1982, 2010.
164. van Kampen CA, Versteeg-van der Voort Maarschalk MF, Langerak-Langerak J, van BE, Roelen DL, Claas FH: Pregnancy can induce long-persisting primed CTLs specific for inherited paternal HLA antigens. *Hum Immunol* 62:201-207, 2001.
165. Aluvihare VR, Kallikourdis M, Betz AG: Tolerance, suppression and the fetal allograft. *J Mol Med* 83:88-96, 2005.
166. Maroni ES, de Sousa MA: The lymphoid organs during pregnancy in the mouse. A comparison between a syngeneic and an allogeneic mating. *Clin Exp Immunol* 13:107-124, 1973.
167. Orgad S, Loewenthal R, Gazit E, Sadetzki S, Novikov I, Carp H: The prognostic value of anti-paternal antibodies and leukocyte immunizations on the proportion of live births in couples with consecutive recurrent miscarriages. *Hum Reprod* 14:2974-2979, 1999.
168. Nielsen HS, Witvliet MD, Steffensen R, Haasnoot GW, Goulmy E, Christiansen OB, Claas F: The presence of HLA-antibodies in recurrent miscarriage patients is associated with a reduced chance of a live birth. *J Reprod Immunol* 2010.

169. Bouma GJ, van CP, van Bree SP, Castelli-Visser RM, Witvliet MD, van der Meer-Prins EM, van Rood JJ, Claas FH: Pregnancy can induce priming of cytotoxic T lymphocytes specific for paternal HLA antigens that is associated with antibody formation. *Transplantation* 62:672-678, 1996.
170. Verdijk RM, Kloosterman A, Pool J, van de KM, Naipal AM, van Halteren AG, Brand A, Mutis T, Goulmy E: Pregnancy induces minor histocompatibility antigen-specific cytotoxic T cells: implications for stem cell transplantation and immunotherapy. *Blood* 103:1961-1964, 2004.
171. van Kampen CA, Versteeg-vd Voort Maarschalk MF, Langerak-Langerak J, Roelen DL, Claas FH: Kinetics of the pregnancy-induced humoral and cellular immune response against the paternal HLA class I antigens of the child. *Hum Immunol* 63:452-458, 2002.
172. Beilke JN, Kuhl NR, Van KL, Gill RG: NK cells promote islet allograft tolerance via a perforin-dependent mechanism. *Nat Med* 11:1059-1065, 2005.
173. Yu G, Xu X, Vu MD, Kilpatrick ED, Li XC: NK cells promote transplant tolerance by killing donor antigen-presenting cells. *J Exp Med* 203:1851-1858, 2006.
174. Sasaki Y, Sakai M, Miyazaki S, Higuma S, Shiozaki A, Saito S: Decidual and peripheral blood CD4+CD25+ regulatory T cells in early pregnancy subjects and spontaneous abortion cases. *Mol Hum Reprod* 10:347-353, 2004.
175. Young NT, Roelen DL, Dallman MJ, Morris PJ, Welsh KI: HLA-DRB1 amino acid disparity is the major stimulus of interleukin-2 production by alloreactive helper T-lymphocytes. *Immunogenetics* 47:310-317, 1998.
176. Sacks GP, Studena K, Sargent K, Redman CW: Normal pregnancy and preeclampsia both produce inflammatory changes in peripheral blood leukocytes akin to those of sepsis. *Am J Obstet Gynecol* 179:80-86, 1998.
177. Luppi P, Haluszczak C, Betters D, Richard CA, Trucco M, DeLoia JA: Monocytes are progressively activated in the circulation of pregnant women. *J Leukoc Biol* 72:874-884, 2002.
178. Kuhnert M, Strohmeier R, Stegmüller M, Halberstadt E: Changes in lymphocyte subsets during normal pregnancy. *Eur J Obstet Gynecol Reprod Biol* 76:147-151, 1998.
179. Watanabe M, Iwatani Y, Kaneda T, Hidaka Y, Mitsuda N, Morimoto Y, Amino N: Changes in T, B, and NK lymphocyte subsets during and after normal pregnancy. *Am J Reprod Immunol* 37:368-377, 1997.
180. Fiddes TM, O'Reilly DB, Cetrulo CL, Miller W, Rudders R, Osband M, Rocklin RE: Phenotypic and functional evaluation of suppressor cells in normal pregnancy and in chronic aborters. *Cell Immunol* 97:407-418, 1986.
181. Matthiesen L, Berg G, Ernerudh J, Skogh T: Lymphocyte subsets and autoantibodies in pregnancies complicated by placental disorders. *Am J Reprod Immunol* 33:31-39, 1995.
182. Luppi P, Haluszczak C, Trucco M, DeLoia JA: Normal pregnancy is associated with peripheral leukocyte activation. *Am J Reprod Immunol* 47:72-81, 2002.
183. Sabahi F, Rola-Pleszczynski M, O'Connell S, Frenkel LD: Qualitative and quantitative analysis of T lymphocytes during normal human pregnancy. *Am J Reprod Immunol* 33:381-393, 1995.
184. Heikkinen J, Mottonen M, Alanen A, Lassila O: Phenotypic characterization of regulatory T cells in the human decidua. *Clin Exp Immunol* 136:373-378, 2004.
185. Somerset DA, Zheng Y, Kilby MD, Sansom DM, Drayson MT: Normal human pregnancy is associated with an elevation in the immune suppressive CD25+ CD4+ regulatory T-cell subset. *Immunology* 112:38-43, 2004.
186. Scherjon S.A.: The immunology of early pregnancy. In Macklon NS, Greer IA, Steegers EAP (eds): *Textbook of periconceptional medicine*. London, Informa Healthcare, 2009.
187. Knobloch V, Jouja V, Pospisil M: Feto-maternal relationship in normal pregnancy in mixed lymphocyte cultures. *Arch Gynakol* 220:249-255, 1976.
188. Steinborn A, Schmitt E, Stein Y, Klee A, Gonser M, Seifried E, Seidl C: Prolonged preterm rupture of fetal membranes, a consequence of an increased maternal anti-fetal T cell responsiveness. *Pediatr Res* 58:648-653, 2005.

189. Visser N, van Rijn BB, Rijkers GT, Franx A, Bruinse HW: Inflammatory changes in preeclampsia: current understanding of the maternal innate and adaptive immune response. *Obstet Gynecol Surv* 62:191-201, 2007.
190. Teran E, Escudero C, Moya W, Flores M, Vallance P, Lopez-Jaramillo P: Elevated C-reactive protein and pro-inflammatory cytokines in Andean women with pre-eclampsia. *Int J Gynaecol Obstet* 75:243-249, 2001.
191. Sacks GP, Redman CW, Sargent IL: Monocytes are primed to produce the Th1 type cytokine IL-12 in normal human pregnancy: an intracellular flow cytometric analysis of peripheral blood mononuclear cells. *Clin Exp Immunol* 131:490-497, 2003.
192. Veenstra van Nieuwenhoven AL, Bouman A, Moes H, Heineman MJ, de Leij LF, Santema J, Faas MM: Cytokine production in natural killer cells and lymphocytes in pregnant women compared with women in the follicular phase of the ovarian cycle. *Fertil Steril* 77:1032-1037, 2002.
193. Ekerfelt C, Matthiesen L, Berg G, Ernerudh J: Paternal leukocytes selectively increase secretion of IL-4 in peripheral blood during normal pregnancies: demonstrated by a novel one-way MLC measuring cytokine secretion. *Am J Reprod Immunol* 38:320-326, 1997.
194. Sakai M, Tsuda H, Tanebe K, Sasaki Y, Saito S: Interleukin-12 secretion by peripheral blood mononuclear cells is decreased in normal pregnant subjects and increased in preeclamptic patients. *Am J Reprod Immunol* 47:91-97, 2002.
195. Higuma-Myojo S, Sasaki Y, Miyazaki S, Sakai M, Siozaki A, Miwa N, Saito S: Cytokine profile of natural killer cells in early human pregnancy. *Am J Reprod Immunol* 54:21-29, 2005.
196. Nakashima A, Ito M, Yoneda S, Shiozaki A, Hidaka T, Saito S: Circulating and decidual Th17 cell levels in healthy pregnancy. *Am J Reprod Immunol* 63:104-109, 2010.
197. Germain SJ, Sacks GP, Sooranna SR, Sargent IL, Redman CW: Systemic inflammatory priming in normal pregnancy and preeclampsia: the role of circulating syncytiotrophoblast microparticles. *J Immunol* 178:5949-5956, 2007.
198. Sargent IL, Borzychowski AM, Redman CW: NK cells and human pregnancy--an inflammatory view. *Trends Immunol* 27:399-404, 2006.
199. Tilburgs T, Roelen DL, van der Mast BJ, van Schip JJ, Kleijburg C, de Groot-Swings GM, Kanhai HH, Claas FH, Scherjon SA: Differential distribution of CD4(+)CD25(bright) and CD8(+)CD28(-) T-cells in decidua and maternal blood during human pregnancy. *Placenta* 27 Suppl A:S47-S53, 2006.
200. van Rood JJ, Eernisse JG, van Leeuwen A.: Leucocyte antibodies in sera from pregnant women. *Nature* 181:1735-1736, 1958.
201. Payne R, Rolf MR.: Fetomaternal leukocyte incompatibility. *J Clin Invest* 37:1756-1763, 1958.
202. Regan L, Braude PR, Hill DP: A prospective study of the incidence, time of appearance and significance of anti-paternal lymphocytotoxic antibodies in human pregnancy. *Hum Reprod* 6:294-298, 1991.
203. Triulzi DJ, Kleinman S, Kakaiya RM, Busch MP, Norris PJ, Steele WR, Glynn SA, Hillyer CD, Carey P, Gottschall JL, Murphy EL, Rios JA, Ness PM, Wright DJ, Carrick D, Schreiber GB: The effect of previous pregnancy and transfusion on HLA alloimmunization in blood donors: implications for a transfusion-related acute lung injury risk reduction strategy. *Transfusion* 49:1825-1835, 2009.
204. Dankers MK, Roelen DL, Korfage N, de LP, Witvliet M, Sandkuijl L, Doxiadis II, Claas FH: Differential immunogenicity of paternal HLA Class I antigens in pregnant women. *Hum Immunol* 64:600-606, 2003.
205. Duquesnoy RJ: The antibody response to an HLA mismatch: a model for nonself-self discrimination in relation to HLA epitope immunogenicity. *Int J Immunogenet* 39:1-9, 2012.
206. Dankers MK, Witvliet MD, Roelen DL, de LP, Korfage N, Persijn GG, Duquesnoy R, Doxiadis II, Claas FH: The number of amino acid triplet differences between patient and donor is predictive for the antibody reactivity against mismatched human leukocyte antigens. *Transplantation* 77:1236-1239, 2004.

207. van Kampen CA, Versteeg-van der Voort Maarschalk MF, Roelen DL, Claas FH: Primed CTLs specific for HLA class I may still be present in sensitized patients when anti-HLA antibodies have disappeared: relevance for donor selection. *Transplantation* 73:1286-1290, 2002.
208. Lachmann N, Terasaki PI, Budde K, Liefeldt L, Kahl A, Reinke P, Pratschke J, Rudolph B, Schmidt D, Salama A, Schonemann C: Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. *Transplantation* 87:1505-1513, 2009.
209. The Trial to Reduce Alloimmunization to Platelets Study Group: Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The Trial to Reduce Alloimmunization to Platelets Study Group. *N Engl J Med* 337:1861-1869, 1997.
210. Middelburg RA, van SD, Briet E, van der Bom JG: The role of donor antibodies in the pathogenesis of transfusion-related acute lung injury: a systematic review. *Transfusion* 48:2167-2176, 2008.
211. Buurma A, Cohen D, Veraa K, Schonkeren D, Claas FH, Bruijn JA, Bloemenkamp KW, Baelde HJ: Preeclampsia is characterized by placental complement dysregulation. *Hypertension* 60:1332-1337, 2012.
212. Cohen D, Visser J, Meuleman T, Claas F, Roelen D.L., Bruijn J, Bajema I.M., Bloemenkamp K.W.M. C4D as a footprint of maternal anti-fetal immunity in recurrent miscarriage; a novel pathogenic mechanism. In press
213. Steinborn A, Seidl C, Sayehli C, Sohn C, Seifried E, Kaufmann M, Schmitt E: Anti-fetal immune response mechanisms may be involved in the pathogenesis of placental abruption. *Clin Immunol* 110:45-54, 2004.
214. Lee J, Romero R, Xu Y, Kim JS, Park JY, Kusanovic JP, Chaiworapongsa T, Hassan SS, Kim CJ: Maternal HLA panel-reactive antibodies in early gestation positively correlate with chronic chorioamnionitis: evidence in support of the chronic nature of maternal anti-fetal rejection. *Am J Reprod Immunol* 66:510-526, 2011.
215. Lee J, Romero R, Xu Y, Kim JS, Topping V, Yoo W, Kusanovic JP, Chaiworapongsa T, Hassan SS, Yoon BH, Kim CJ: A signature of maternal anti-fetal rejection in spontaneous preterm birth: chronic chorioamnionitis, anti-human leukocyte antigen antibodies, and C4d. *PLoS One* 6:e16806, 2011.
216. Bartel G, Walch K, Wahrmann M, Pils S, Kussel L, Polterauer S, Tempfer C, Bohmig GA: Prevalence and qualitative properties of circulating anti-human leukocyte antigen alloantibodies after pregnancy: no association with unexplained recurrent miscarriage. *Hum Immunol* 72:187-192, 2011.
217. Steinborn A, Saran G, Schneider A, Fersis N, Sohn C, Schmitt E: The presence of gestational diabetes is associated with increased detection of anti-HLA-class II antibodies in the maternal circulation. *Am J Reprod Immunol* 56:124-134, 2006.
218. Kishore R, Agarwal S, Halder A, Das V, Shukla BR, Agarwal SS: HLA sharing, anti-paternal cytotoxic antibodies and MLR blocking factors in women with recurrent spontaneous abortion. *J Obstet Gynaecol Res* 22:177-183, 1996.
219. Fujisawa S: HLA antigens-antibodies system and its association with severe toxemia of pregnancy. *Nihon Sanka Fujinka Gakkai Zasshi* 37:124-130, 1985.
220. Jenkins DM, Need J, Kajah SM: Deficiency of specific HLA antibodies in severe pregnancy pre-eclampsia/eclampsia. *Clin Exp Immunol* 27:485-486, 1977.
221. Bolis PF, Martinetti BM, La FA, Franchi M, Cuccia BM: Immunogenetic aspects of preeclampsia. *Biol Res Pregnancy Perinatol* 8:42-45, 1987.
222. Coulam CB: Immunologic tests in the evaluation of reproductive disorders: a critical review. *Am J Obstet Gynecol* 167:1844-1851, 1992.
223. Biddle PK, Friedman CI, Johnson PM: Lymphocyte-reactive antibodies and recurrent early pregnancy failure. *Am J Obstet Gynecol* 157:785-786, 1987.

224. Agrawal S, Pandey MK, Mandal S, Mishra L, Agarwal S: Humoral immune response to an allogenic foetus in normal fertile women and recurrent aborters. *BMC Pregnancy Childbirth* 2:6, 2002.
225. Sargent IL, Wilkins T, Redman CW: Maternal immune responses to the fetus in early pregnancy and recurrent miscarriage. *Lancet* 2:1099-1104, 1988.
226. Umapathy S, Shankarkumar A, Ramrakhiyani V, Ghosh K: Role of anti-human lymphocyte culture cytotoxic antibodies in recurrent spontaneous pregnancy loss women. *J Hum Reprod Sci* 4:17-19, 2011.
227. Shankarkumar U, Pradhan VD, Patwardhan MM, Shankarkumar A, Ghosh K: Autoantibody profile and other immunological parameters in recurrent spontaneous abortion patients. *Niger Med J* 52:163-166, 2011.
228. Souza SS, Ferriani RA, Santos CM, Voltarelli JC: Immunological evaluation of patients with recurrent abortion. *J Reprod Immunol* 56:111-121, 2002.
229. Terasaki PI, Bernoco D, Park MS, Ozturk G, Iwaki Y: Microdroplet testing for HLA-A, -B, -C, and -D antigens. The Phillip Levine Award Lecture. *Am J Clin Pathol* 69:103-120, 1978.
230. Zachary AA, Kopchaliiska D, Jackson AM, Leffell MS: Immunogenetics and immunology in transplantation. *Immunol Res* 47:232-239, 2010.
231. Adeyi OA, Girnita AL, Howe J, Marrari M, Awadalla Y, Askar M, Martell J, Zeevi A, Shapiro R, Nalesnik M, Randhawa P, Demetris AJ, Duquesnoy RJ: Serum analysis after transplant nephrectomy reveals restricted antibody specificity patterns against structurally defined HLA class I mismatches. *Transpl Immunol* 14:53-62, 2005.
232. Saftlas AF, Levine RJ, Klebanoff MA, Martz KL, Ewell MG, Morris CD, Sibai BM: Abortion, changed paternity, and risk of preeclampsia in nulliparous women. *Am J Epidemiol* 157:1108-1114, 2003.
233. Saftlas AF, Beydoun H, Triche E: Immunogenetic determinants of preeclampsia and related pregnancy disorders: a systematic review. *Obstet Gynecol* 106:162-172, 2005.
234. Robillard PY, Hulseley TC, Perianin J, Janky E, Miri EH, Papiernik E: Association of pregnancy-induced hypertension with duration of sexual cohabitation before conception. *Lancet* 344:973-975, 1994.
235. Robertson SA, Guerin LR, Bromfield JJ, Branson KM, Ahlstrom AC, Care AS: Seminal fluid drives expansion of the CD4+CD25+ T regulatory cell pool and induces tolerance to paternal alloantigens in mice. *Biol Reprod* 80:1036-1045, 2009.
236. Ariga H, Ohto H, Busch MP, Imamura S, Watson R, Reed W, Lee TH: Kinetics of fetal cellular and cell-free DNA in the maternal circulation during and after pregnancy: implications for noninvasive prenatal diagnosis. *Transfusion* 41:1524-1530, 2001.
237. Bianchi DW, Zickwolf GK, Weil GJ, Sylvester S, DeMaria MA: Male fetal progenitor cells persist in maternal blood for as long as 27 years postpartum. *Proc Natl Acad Sci U S A* 93:705-708, 1996.
238. Bianchi DW, Farina A, Weber W, Delli-Bovi LC, Deriso M, Williams JM, Klinger KW: Significant fetal-maternal hemorrhage after termination of pregnancy: implications for development of fetal cell microchimerism. *Am J Obstet Gynecol* 184:703-706, 2001.
239. Khosrotehrani K, Johnson KL, Lau J, Dupuy A, Cha DH, Bianchi DW: The influence of fetal loss on the presence of fetal cell microchimerism: a systematic review. *Arthritis Rheum* 48:3237-3241, 2003.
240. Al-Mufti R, Hambley H, Albaiges G, Lees C, Nicolaides KH: Increased fetal erythroblasts in women who subsequently develop pre-eclampsia. *Hum Reprod* 15:1624-1628, 2000.
241. Holzgreve W, Ghezzi F, Di NE, Ganshirt D, Maymon E, Hahn S: Disturbed feto-maternal cell traffic in preeclampsia. *Obstet Gynecol* 91:669-672, 1998.
242. Al-Mufti R, Lees C, Albaiges G, Hambley H, Nicolaides KH: Fetal cells in maternal blood of pregnancies with severe fetal growth restriction. *Hum Reprod* 15:218-221, 2000.

243. Simchen MJ, Barkai G, Lusky A, Guetta E: Fetal hemoglobin-expressing nucleated red blood cell frequencies in pregnancies with intrauterine growth restriction. *Prenat Diagn* 21:31-35, 2001.
244. Roelen DL, Doxiadis II, Claas FH: Detection and clinical relevance of donor specific HLA antibodies: a matter of debate. *Transpl Int* 25:604-610, 2012.
245. Ting A, Morris PJ: Successful transplantation with a positive T and B cell crossmatch due to autoreactive antibodies. *Tissue Antigens* 21:219-226, 1983.
246. Lee J, Romero R, Dong Z, Xu Y, Qureshi F, Jacques S, Yoo W, Chaiworapongsa T, Mittal P, Hassan SS, Kim CJ: Unexplained fetal death has a biological signature of maternal anti-fetal rejection: chronic chorioamnionitis and alloimmune anti-human leucocyte antigen antibodies. *Histopathology* 59:928-938, 2011.
247. Zoet YM, Brand-Schaaf SH, Roelen DL, Mulder A, Claas FH, Doxiadis II: Challenging the golden standard in defining donor-specific antibodies: does the solid phase assay meet the expectations? *Tissue Antigens* 77:225-228, 2011.
248. Morales-Buenrostro LE, Terasaki PI, Marino-Vazquez LA, Lee JH, El-Awar N, Alberu J: "Natural" human leukocyte antigen antibodies found in nonalloimmunized healthy males. *Transplantation* 86:1111-1115, 2008.
249. Zoet YM, Eijssink C, Bohmova R, Witvliet MD, Kardol MJ, Franke ME, Claas FH, Mulder A, Doxiadis II: Single-antigen-expressing cell lines are excellent tools for detecting human leukocyte antigen-C-reactive antibodies in kidney transplant recipients. *Transplantation* 79:1268-1272, 2005.
250. King KE, Kao KJ, Bray PF, Casella JF, Blakemore K, Callan NA, Kennedy SD, Kickler TS: The role of HLA antibodies in neonatal thrombocytopenia: a prospective study. *Tissue Antigens* 47:206-211, 1996.
251. Tanaka T, Umesaki N, Nishio J, Maeda K, Kawamura T, Araki N, Ogita S: Neonatal thrombocytopenia induced by maternal anti-HLA antibodies: a potential side effect of allogeneic leukocyte immunization for unexplained recurrent aborters. *J Reprod Immunol* 46:51-57, 2000.
252. van der Hoorn ML, van EA, Swings GM, van BE, van der Keur C, Tirado-Gonzalez I, Blois SM, Karumanchi SA, Bianchi DW, Claas FH, Scherjon SA: Differential immunoregulation in successful oocyte donation pregnancies compared with naturally conceived pregnancies. *J Reprod Immunol* 2013.
253. Verduyn W, Doxiadis II, Anholts J, Drabbels JJ, Naipal A, D'Amato J, Persijn GG, Giphart MJ, Schreuder GM: Biotinylated DRB sequence-specific oligonucleotides. Comparison to serologic HLA-DR typing of organ donors in eurotransplant. *Hum Immunol* 37:59-67, 1993.
254. Duquesnoy RJ: HLA-Matchmaker: a molecularly based algorithm for histocompatibility determination. I. Description of the algorithm. *Hum Immunol* 63:339-352, 2002.
255. Billen EV, Voorter CE, Christiaans MH, van den Berg-Loonen EM: Luminex donor-specific crossmatches. *Tissue Antigens* 71:507-513, 2008.
256. Steyerberg EW, Eijkemans MJ, Harrell FE, Jr., Habbema JD: Prognostic modelling with logistic regression analysis: a comparison of selection and estimation methods in small data sets. *Stat Med* 19:1059-1079, 2000.
257. Smithey MJ, Li G, Venturi V, Davenport MP, Nikolich-Zugich J: Lifelong persistent viral infection alters the naive T cell pool, impairing CD8 T cell immunity in late life. *J Immunol* 189:5356-5366, 2012.
258. David M, Smidt J, Chen FC, Stein U, Dudenhausen JW: Risk factors for fetal-to-maternal transfusion in Rh D-negative women--results of a prospective study on 942 pregnant women. *J Perinat Med* 32:254-257, 2004.
259. Honger G, Fornaro I, Granado C, Tiercy JM, Hosli I, Schaub S: Frequency and Determinants of Pregnancy-Induced Child-Specific Sensitization. *Am J Transplant* 2013.
260. Verduin EP, Schonewille H, Brand A, Haasnoot GW, Claas FH, Lindenburg IT, Lopriore E, Oepkes D, Roelen DL, Doxiadis II: High anti-HLA response in women exposed to intrauterine

- transfusions for severe alloimmune hemolytic disease is associated with mother-child HLA triplet mismatches, high anti-D titer, and new red blood cell antibody formation. *Transfusion* 2012.
261. Maruya E, Sasaki N, El-Awar N, Akaza T, Kitawaki J, Saji H, Terasaki PI: Immunogenic HLA class I epitopes identified by humoral response to pregnancies. *Clin Transpl* 215-227, 2008.
 262. Dankers MK, Roelen DL, Nagelkerke NJ, de LP, Persijn GG, Doxiadis II, Claas FH: The HLA-DR phenotype of the responder is predictive of humoral response against HLA class I antigens. *Hum Immunol* 65:13-19, 2004.
 263. Fuller TC, Fuller A: The humoral immune response against an HLA class I allodeterminant correlates with the HLA-DR phenotype of the responder. *Transplantation* 68:173-182, 1999.
 264. Doxiadis II, Rahmel A, Claas FH: Towards kidney allocation on basis of HLA-DR compatibility. *Clin Transpl* 61-64, 2010.
 265. Doxiadis II, de Fijter JW, Mallat MJ, Haasnoot GW, Ringers J, Persijn GG, Claas FH: Simpler and equitable allocation of kidneys from postmortem donors primarily based on full HLA-DR compatibility. *Transplantation* 83:1207-1213, 2007.
 266. Chernyshov VP, Tumanova LE, Sudoma IA, Bannikov VI: Th1 and Th2 in human IVF pregnancy with allogenic fetus. *Am J Reprod Immunol* 59:352-358, 2008.
 267. Mosmann TR, Sad S: The expanding universe of T-cell subsets: Th1, Th2 and more. *Immunol Today* 17:138-146, 1996.
 268. Middelburg RA, Porcelijn L, Lardy N, Briet E, Vrielink H: Prevalence of leucocyte antibodies in the Dutch donor population. *Vox Sang* 100:327-335, 2011.
 269. Powers A, Stowell CP, Dzik WH, Saidman SL, Lee H, Makar RS: Testing only donors with a prior history of pregnancy or transfusion is a logical and cost-effective transfusion-related acute lung injury prevention strategy. *Transfusion* 48:2549-2558, 2008.
 270. Alberu J, Morales-Buenrostro LE, de LC, Vargas-Rojas MI, Marino-Vazquez LA, Crispin JC: A non-allogeneic stimulus triggers the production of de novo HLA antibodies in healthy adults. *Transpl Immunol* 18:166-171, 2007.
 271. Dickinson AM, Wang XN, Sviland L, Vyth-Dreese FA, Jackson GH, Schumacher TN, Haanen JB, Mutis T, Goulmy E: In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens. *Nat Med* 8:410-414, 2002.
 272. Doxiadis II, Smits JM, Schreuder GM, Persijn GG, van Houwelingen HC, van Rood JJ, Claas FH: Association between specific HLA combinations and probability of kidney allograft loss: the taboo concept. *Lancet* 348:850-853, 1996.
 273. Williams Z, Zepf D, Longtine J, Anchan R, Broadman B, Missmer SA, Hornstein MD: Foreign fetal cells persist in the maternal circulation. *Fertil Steril* 91:2593-2595, 2009.
 274. Babbage SJ, Arkwright PD, Vince GS, Perrey C, Pravica V, Quenby S, Bates M, Hutchinson IV: Cytokine promoter gene polymorphisms and idiopathic recurrent pregnancy loss. *J Reprod Immunol* 51:21-27, 2001.
 275. Lashley EE, Meuleman T, Claas FH: Beneficial or Harmful Effect of Antipaternal Human Leukocyte Antibodies on Pregnancy Outcome? A Systematic Review and Meta-Analysis. *Am J Reprod Immunol* 70:87-103, 2013.
 276. Lutjen P, Trounson A, Leeton J, Findlay J, Wood C, Renou P: The establishment and maintenance of pregnancy using in vitro fertilization and embryo donation in a patient with primary ovarian failure. *Nature* 307:174-175, 1984.
 277. Levron Y, Dviri M, Segol I, Yerushalmi GM, Hourvitz A, Orvieto R, Mazaki-Tovi S, Yinon Y: The 'immunologic theory' of preeclampsia revisited: a lesson from donor oocyte gestations. *Am J Obstet Gynecol* 2014.
 278. Abdalla HI, Billett A, Kan AK, Baig S, Wren M, Korea L, Studd JW: Obstetric outcome in 232 ovum donation pregnancies. *Br J Obstet Gynaecol* 105:332-337, 1998.
 279. Wiggins DA, Main E: Outcomes of pregnancies achieved by donor egg in vitro fertilization--a comparison with standard in vitro fertilization pregnancies. *Am J Obstet Gynecol* 192:2002-2006, 2005.

280. Klatsky PC, Delaney SS, Caughey AB, Tran ND, Schattman GL, Rosenwaks Z: The role of embryonic origin in preeclampsia: a comparison of autologous in vitro fertilization and ovum donor pregnancies. *Obstet Gynecol* 116:1387-1392, 2010.
281. Salmon JE, Heuser C, Triebwasser M, Liszewski MK, Kavanagh D, Roumenina L, Branch DW, Goodship T, Fremeaux-Bacchi V, Atkinson JP: Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort. *PLoS Med* 8:e1001013, 2011.
282. Derzsy Z, Prohaszka Z, Rigo J, Jr., Fust G, Molvarec A: Activation of the complement system in normal pregnancy and preeclampsia. *Mol Immunol* 47:1500-1506, 2010.
283. Kestlerova A, Feyereisl J, Frisova V, Mechurova A, Sula K, Zima T, Belacek J, Madar J: Immunological and biochemical markers in preeclampsia. *J Reprod Immunol* 96:90-94, 2012.
284. Houwert-de Jong MH, Claas FH, Gmelig-Meyling FH, Kalsbeek GL, Valentijn RM, te Velde ER, Schuurman HJ: Humoral immunity in normal and complicated pregnancy. *Eur J Obstet Gynecol Reprod Biol* 19:205-214, 1985.
285. Sinha D, Wells M, Faulk WP: Immunological studies of human placentae: complement components in pre-eclamptic chorionic villi. *Clin Exp Immunol* 56:175-184, 1984.
286. Tedesco F, Radillo O, Candussi G, Nazzaro A, Mollnes TE, Pecorari D: Immunohistochemical detection of terminal complement complex and S protein in normal and pre-eclamptic placentae. *Clin Exp Immunol* 80:236-240, 1990.
287. Gundogan F, Bianchi DW, Scherjon SA, Roberts DJ: Placental pathology in egg donor pregnancies. *Fertil Steril* 93:397-404, 2009.
288. Saftlas AF, Beydoun H, Triche E: Immunogenetic determinants of preeclampsia and related pregnancy disorders: a systematic review. *Obstet Gynecol* 106:162-172, 2005.
289. Beydoun H, Saftlas AF: Association of human leucocyte antigen sharing with recurrent spontaneous abortions. *Tissue Antigens* 65:123-135, 2005.
290. Soderstrom-Anttila V, Sajaniemi N, Tiitinen A, Hovatta O: Health and development of children born after oocyte donation compared with that of those born after in-vitro fertilization, and parents' attitudes regarding secrecy. *Hum Reprod* 13:2009-2015, 1998.
291. Sauer MV, Paulson RJ, Lobo RA: Oocyte donation to women of advanced reproductive age: pregnancy results and obstetrical outcomes in patients 45 years and older. *Hum Reprod* 11:2540-2543, 1996.
292. Abramson SB, Buyon JP: Activation of the complement pathway: comparison of normal pregnancy, preeclampsia, and systemic lupus erythematosus during pregnancy. *Am J Reprod Immunol* 28:183-187, 1992.
293. Girardi G, Berman J, Redecha P, Spruce L, Thurman JM, Kraus D, Hollmann TJ, Casali P, Caroll MC, Wetsel RA, Lambris JD, Holers VM, Salmon JE: Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. *J Clin Invest* 112:1644-1654, 2003.
294. Holers VM, Girardi G, Mo L, Guthridge JM, Molina H, Pierangeli SS, Espinola R, Xiaowei LE, Mao D, Vialpando CG, Salmon JE: Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. *J Exp Med* 195:211-220, 2002.
295. Tacnet-Delorme P, Chevallier S, Arlaud GJ: Beta-amyloid fibrils activate the C1 complex of complement under physiological conditions: evidence for a binding site for A beta on the C1q globular regions. *J Immunol* 167:6374-6381, 2001.
296. Mold C, Gewurz H, Du Clos TW: Regulation of complement activation by C-reactive protein. *Immunopharmacology* 42:23-30, 1999.
297. Weiser MR, Williams JP, Moore FD, Jr., Kobzik L, Ma M, Hechtman HB, Carroll MC: Reperfusion injury of ischemic skeletal muscle is mediated by natural antibody and complement. *J Exp Med* 183:2343-2348, 1996.
298. Buurma A, Veraar K, Cohen D, Goemaere N, Bruijn JA, Bloemenkamp K.W.M., Baelde HJ. Placental complement activation is related to placental dysfunction in the setting of preeclampsia. 2013. Thesis

299. Salha O, Sharma V, Dada T, Nugent D, Rutherford AJ, Tomlinson AJ, Philips S, Allgar V, Walker JJ: The influence of donated gametes on the incidence of hypertensive disorders of pregnancy. *Hum Reprod* 14:2268-2273, 1999.
300. Schonkeren D, Swings G, Roberts D, Claas F, de HE, Scherjon S: Pregnancy close to the edge: an immunosuppressive infiltrate in the chorionic plate of placentas from uncomplicated egg cell donation. *PLoS One* 7:e32347, 2012.
301. Coulam CB: Epidemiology of recurrent spontaneous abortion. *Am J Reprod Immunol* 26:23-27, 1991.
302. Larsen EC, Christiansen OB, Kolte AM, Macklon N: New insights into mechanisms behind miscarriage. *BMC Med* 11:154, 2013.
303. Rai R, Regan L: Recurrent miscarriage. *Lancet* 368:601-611, 2006.
304. Kruse C, Steffensen R, Varming K, Christiansen OB: A study of HLA-DR and -DQ alleles in 588 patients and 562 controls confirms that HLA-DRB1*03 is associated with recurrent miscarriage. *Hum Reprod* 19:1215-1221, 2004.
305. Aruna M, Nagaraja T, Andal BS, Tarakeswari S, Reddy AG, Thangaraj K, Singh L, Reddy BM: Novel alleles of HLA-DQ and -DR loci show association with recurrent miscarriages among South Indian women. *Hum Reprod* 26:765-774, 2011.
306. Klein J, Sato A: The HLA system. Second of two parts. *N Engl J Med* 343:782-786, 2000.
307. Faridi RM, Agrawal S: Killer immunoglobulin-like receptors (KIRs) and HLA-C allorecognition patterns implicative of dominant activation of natural killer cells contribute to recurrent miscarriages. *Hum Reprod* 26:491-497, 2011.
308. Hiby SE, Regan L, Lo W, Farrell L, Carrington M, Moffett A: Association of maternal killer-cell immunoglobulin-like receptors and parental HLA-C genotypes with recurrent miscarriage. *Hum Reprod* 23:972-976, 2008.
309. Hiby SE, Walker JJ, O'shaughnessy KM, Redman CW, Carrington M, Trowsdale J, Moffett A: Combinations of maternal KIR and fetal HLA-C genes influence the risk of preeclampsia and reproductive success. *J Exp Med* 200:957-965, 2004.
310. Varla-Leftherioti M, Spyropoulou-Vlachou M, Keramitsoglou T, Papadimitropoulos M, Tsekoura C, Graphou O, Papadopoulou C, Gerondi M, Stavropoulos-Giokas C: Lack of the appropriate natural killer cell inhibitory receptors in women with spontaneous abortion. *Hum Immunol* 66:65-71, 2005.
311. Nowak I, Malinowski A, Tchorzewski H, Barcz E, Wilczynski JR, Banasik M, Grybos M, Kurpisz M, Luszczek W, Majorczyk E, Wisniewski A, Senitzer D, Sun JY, Kusnierczyk P: HLA-C C1C2 heterozygosity may protect women bearing the killer immunoglobulin-like receptor AA genotype from spontaneous abortion. *J Reprod Immunol* 88:32-37, 2011.
312. Hiby SE, Apps R, Sharkey AM, Farrell LE, Gardner L, Mulder A, Claas FH, Walker JJ, Redman CW, Morgan L, Tower C, Regan L, Moore GE, Carrington M, Moffett A: Maternal activating KIRs protect against human reproductive failure mediated by fetal HLA-C2. *J Clin Invest* 120:4102-4110, 2010.
313. Vargas RG, Sarturi PR, Mattar SB, Bompeixe EP, Silva JS, Pirri A, Bicalho MG: Association of HLA-G alleles and 3' UTR 14 bp haplotypes with recurrent miscarriage in Brazilian couples. *Hum Immunol* 72:479-485, 2011.
314. Pfeiffer KA, Fimmers R, Engels G, van d, V, van d, V: The HLA-G genotype is potentially associated with idiopathic recurrent spontaneous abortion. *Mol Hum Reprod* 7:373-378, 2001.
315. Christiansen OB, Kolte AM, Dahl M, Larsen EC, Steffensen R, Nielsen HS, Hviid TV: Maternal homozygosity for a 14 base pair insertion in exon 8 of the HLA-G gene and carriage of HLA class II alleles restricting HY immunity predispose to unexplained secondary recurrent miscarriage and low birth weight in children born to these patients. *Human Immunology* 73:699-705, 2012.
316. Xue S, Yang J, Yao F, Xu L, Fan L: Recurrent spontaneous abortions patients have more -14 bp/+14 bp heterozygotes in the 3'UT region of the HLA-G gene in a Chinese Han population. *Tissue Antigens* 69 Suppl 1:153-155, 2007.

317. Hviid TV, Hylenius S, Rorbye C, Nielsen LG: HLA-G allelic variants are associated with differences in the HLA-G mRNA isoform profile and HLA-G mRNA levels. *Immunogenetics* 55:63-79, 2003.
318. Chen XY, Yan WH, Lin A, Xu HH, Zhang JG, Wang XX: The 14 bp deletion polymorphisms in HLA-G gene play an important role in the expression of soluble HLA-G in plasma. *Tissue Antigens* 72:335-341, 2008.
319. Hviid TV, Rizzo R, Christiansen OB, Melchiorri L, Lindhard A, Baricordi OR: HLA-G and IL-10 in serum in relation to HLA-G genotype and polymorphisms. *Immunogenetics* 56:135-141, 2004.
320. Beydoun H, Saftlas AF: Association of human leucocyte antigen sharing with recurrent spontaneous abortions. *Tissue Antigens* 65:123-135, 2005.
321. Christiansen OB, Ring M, Rosgaard A, Grunnet N, Gluud C: Association between HLA-DR1 and -DR3 antigens and unexplained repeated miscarriage. *Hum Reprod Update* 5:249-255, 1999.
322. Wang X, Jiang W, Zhang D: Association of 14-bp insertion/deletion polymorphism of HLA-G gene with unexplained recurrent spontaneous abortion: a meta-analysis. *Tissue Antigens* 81:108-115, 2013.
323. Fan W, Li S, Huang Z, Chen Q: Relationship between HLA-G polymorphism and susceptibility to recurrent miscarriage: A meta-analysis of non-family-based studies. *J Assist Reprod Genet* 31:173-184, 2013.
324. Beydoun H, Saftlas AF: Association of human leucocyte antigen sharing with recurrent spontaneous abortions. *Tissue Antigens* 65:123-135, 2005.
325. Royal College of Obstetricians and Gynaecologists: The investigation and treatment of couples with recurrent first-trimester and second-trimester miscarriage. *Green-top Guideline No 17* 2011.
326. The Practice Committee of the American Society for Reproductive Medicine: Evaluation and treatment of recurrent pregnancy loss: a committee opinion. *Fertility and Sterility* 98:1103-1111, 2011.
327. Dutch Society of Obstetrics and Gynaecology: Habitual abortion. *Guideline no 20* 1999.
328. Zachary AA, Kopchaliiska D, Jackson AM, Leffell MS: Immunogenetics and immunology in transplantation. *Immunol Res* 47:232-239, 2010.
329. Hartung K, Fontana A, Klar M, Krippner H, Jorgens K, Lang B, Peter HH, Pichler WJ, Schendel D, Robin-Winn M,: Association of class I, II, and III MHC gene products with systemic lupus erythematosus. Results of a Central European multicenter study. *Rheumatol Int* 9:13-18, 1989.
330. Peart E, Clowse ME: Systemic lupus erythematosus and pregnancy outcomes: an update and review of the literature. *Curr Opin Rheumatol* 26:118-123, 2014.
331. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ: The 1982 revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum* 25:1271-1277, 1982.
332. Hochberg MC: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum* 40:1725, 1997.
333. Nelson JL, Hansen JA: Autoimmune diseases and HLA. *Crit Rev Immunol* 10:307-328, 1990.
334. Shelton AJ, Harger JH, Dorman JS, Kuller LH, LaPorte RE, Gill TJ, III: Association between familial autoimmune diseases and recurrent spontaneous abortions. *Am J Reprod Immunol* 32:82-87, 1994.
335. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Menard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovsky J, Wolfe F, Hawker G: Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. *Arthritis Rheum* 62:2569-2581, 2010.

336. Poli F, Scalomogna M, Crespiatico L, Macchi B, Misto R, Nocco A, Rossini G, Scarpino C, Sioli V, Sirchia G: Comparison of serological and molecular typing for HLA-A and -B on cord blood lymphocytes. *Tissue Antigens* 51:67-71, 1998.
337. Woszczek G, Borowiec M, Mis M, Gorska M, Kowalski ML: Comparison of serological and molecular (PCR-SSP) techniques of HLA-DR typing in clinical laboratory routine. *Ann Transplant* 2:39-42, 1997.
338. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. *Introduction to meta-analysis*. 2009.
339. The-Cochrane-Collaboration: *Cochrane handbook for systematic reviews of interventions*. 2008.
340. Jirous J, Diejomaoh M, Al-Othman S, Al-Abdulhadi F, Al-Marzouk N, Sugathan T: A correlation of the uterine and ovarian blood flows with parity of nonpregnant women having a history of recurrent spontaneous abortions. *Gynecol Obstet Invest* 52:51-54, 2001.
341. Yokoo T, Takakuwa K, Mitsui T, Honda K, Kaibe M, Ishii K, Kikuchi A, Tamura M, Tanaka K: Compatibility of HLA-A and -B antigens in patients with unexplained recurrent abortion. *Acta Medica et Biologica* 53:43-49, 2005.
342. Mueller-Eckhardt G, Mallmann P, Neppert J, Lattermann A, Melk A, Heine O, Pfeiffer R, Zingsem J, Domke N, Mohr-Pennert A: Immunogenetic and serological investigations in nonpregnant and in pregnant women with a history of recurrent spontaneous abortions. *Journal of Reproductive Immunology* 27:95-109, 1994.
343. Kano T, Mori T, Furudono M, Ishikawa H, Watanabe H, Kikkawa E, Warita T, Onizuka M, Takahashi M, Maeda Y, Naruse T, Inoko H, Kimura A: Human leukocyte antigen may predict outcome of primary recurrent spontaneous abortion treated with paternal lymphocyte alloimmunization therapy. *Am J Reprod Immunol* 58:383-387, 2007.
344. Wang S, Zhao YR, Jiao YL, Wang LC, Li JF, Cui B, Xu CY, Shi YH, Chen ZJ: Increased activating killer immunoglobulin-like receptor genes and decreased specific HLA-C alleles in couples with recurrent spontaneous abortion. *Biochem Biophys Res Commun* 360:696-701, 2007.
345. Dizon-Townson D, Nelson L, Scott JR, Branch DW, Ward K: Human leukocyte antigen DQ alpha sharing is not increased in couples with recurrent miscarriage. *Am J Reprod Immunol* 34:209-212, 1995.
346. Zhu Y, Huo Z, Lai J, Li S, Jiao H, Dang J, Jin C: Case-control study of a HLA-G 14-bp insertion-deletion polymorphism in women with recurrent miscarriages. *Scand J Immunol* 71:52-54, 2010.
347. Yan WH, Lin A, Chen XJ, Dai MZ, Gan LH, Zhou MY, Zhu M, Shi WW, Liu JM: Association of the maternal 14-bp insertion polymorphism in the HLA-G gene in women with recurrent spontaneous abortions. *Tissue Antigens* 68:521-523, 2006.
348. Yan WH, Fan LA, Yang JQ, Xu LD, Ge Y, Yao FJ: HLA-G polymorphism in a Chinese Han population with recurrent spontaneous abortion. *Int J Immunogenet* 33:55-58, 2006.
349. Giannakopoulos B, Passam F, Ioannou Y, Krilis SA: How we diagnose the antiphospholipid syndrome. *Blood* 113:985-994, 2009.
350. Chang MY, Soong YK, Huang CC: Comparison of histocompatibility between couples with idiopathic recurrent spontaneous abortion and normal multipara. *J Formos Med Assoc* 90:153-159, 1991.
351. Suryanarayana V, Rao L, Kanakavalli M, Padmalatha V, Raseswari T, Deenadayal M, Singh L: Association between novel HLA-G genotypes and risk of recurrent miscarriages: a case-control study in a South Indian population. *Reprod Sci* 15:817-824, 2008.
352. Kanai T, Fujii T, Keicho N, Tokunaga K, Yamashita T, Hyodo H, Miki A, Unno N, Kozuma S, Taketani Y: Polymorphism of human leukocyte antigen-E gene in the Japanese population with or without recurrent abortion. *Am J Reprod Immunol* 45:168-173, 2001.
353. Ober C, Steck T, van d, V, Billstrand C, Messer L, Kwak J, Beaman K, Beer A: MHC class II compatibility in aborted fetuses and term infants of couples with recurrent spontaneous abortion. *J Reprod Immunol* 25:195-207, 1993.

354. Kishore R, Agarwal S, Halder A, Das V, Shukla BR, Agarwal SS: HLA sharing, anti-paternal cytotoxic antibodies and MLR blocking factors in women with recurrent spontaneous abortion. *J Obstet Gynaecol Res* 22:177-183, 1996.
355. Eroglu G, Betz G, Torregano C: Impact of histocompatibility antigens on pregnancy outcome. *Am J Obstet Gynecol* 166:1364-1369, 1992.
356. Oksenberg JR, Persitz E, Amar A, Brautbar C: Maternal-paternal histocompatibility: lack of association with habitual abortions. *Fertil Steril* 42:389-395, 1984.
357. Sasaki T, Yamada H, Kato EH, Sudo S, Kishida T, Sasaki T, Nishigaki F, Fujimoto S: Increased frequency of HLA-DR4 allele in women with unexplained recurrent spontaneous abortions, detected by the method of PCR-SSP. *J Reprod Immunol* 32:273-279, 1997.
358. Johnson PM, Chia KV, Risk JM, Barnes RM, Woodrow JC: Immunological and immunogenetic investigation of recurrent spontaneous abortion. *Dis Markers* 6:163-171, 1988.
359. Takakuwa K, Honda K, Yokoo T, Hataya I, Tamura M, Tanaka K: Molecular genetic studies on the compatibility of HLA class II alleles in patients with unexplained recurrent miscarriage in the Japanese population. *Clin Immunol* 118:101-107, 2006.
360. Takakuwa K, Hataya I, Arakawa M, Kikuchi A, Higashino M, Yasuda M, Kurabayashi T, Tanaka K: Possible susceptibility of the HLA-DPB1*0402 and HLA-DPB1*04 alleles to unexplained recurrent abortion: analysis by means of polymerase chain reaction-restricted fragment length polymorphism method. *Am J Reprod Immunol* 42:233-239, 1999.
361. Christiansen OB, Mohapeloa HP, Steffensen R, Jersild C: HLA-C and -Bw typing of couples with unexplained recurrent miscarriages. *J Reprod Immunol* 37:63-77, 1997.
362. Bellingard V, Hedon B, Eliaou JF, Seignalet J, Clot J, Viala JL: Immunogenetic study of couples with recurrent spontaneous abortions. *Eur J Obstet Gynecol Reprod Biol* 60:53-60, 1995.
363. Takakuwa K, Higashino M, Ueda H, Yamada K, Asano K, Yasuda M, Ishii S, Kazama Y, Tanaka K: Significant compatibility does not exist at the HLA-DQB gene locus in couples with unexplained recurrent abortions. *Am J Reprod Immunol* 28:12-16, 1992.
364. Christiansen OB, Riisom K, Lauritsen JG, Grunnet N: No increased histocompatibility antigen-sharing in couples with idiopathic habitual abortions. *Hum Reprod* 4:160-162, 1989.
365. Takakuwa K, Adachi H, Hataya I, Ishii K, Tamura M, Tanaka K: Molecular genetic studies of HLA-DRB1 alleles in patients with unexplained recurrent abortion in the Japanese population. *Hum Reprod* 18:728-733, 2003.
366. Abbas A, Tripathi P, Naik S, Agrawal S: Analysis of human leukocyte antigen (HLA)-G polymorphism in normal women and in women with recurrent spontaneous abortions. *Eur J Immunogenet* 31:275-278, 2004.
367. Tripathi P, Abbas A, Naik S, Agrawal S: Role of 14-bp deletion in the HLA-G gene in the maintenance of pregnancy. *Tissue Antigens* 64:706-710, 2004.
368. Tripathi P, Naik S, Agrawal S: HLA-E*0101 associated with recurrent spontaneous abortion. *Journal of the Turkish German Gynecology Association* 8:278-282, 2007.
369. Mosaad YM, Abdel-Dayem Y, El-Deek BS, El-Sherbini SM: Association between HLA-E *0101 homozygosity and recurrent miscarriage in Egyptian women. *Scand J Immunol* 74:205-209, 2011.
370. Tripathi P, Naik S, Agrawal S: HLA-E and immunobiology of pregnancy. *Tissue Antigens* 67:207-213, 2006.
371. Laurentaci G, Nappi L: Analysis of association of HLA-DR antigens and autoimmunity in recurrent spontaneous abortions. *Italian Journal of Gynaecology and Obstetrics* 11:62-67, 1999.
372. Sbracia M, Mastrone M, Scarpellini F, Grasso JA: Influence of histocompatibility antigens in recurrent spontaneous abortion couples and on their reproductive performances. *Am J Reprod Immunol* 35:85-92, 1996.
373. Ho HN, Gill TJ, Nsieh RP, Hsieh HJ, Lee TY: Sharing of human leukocyte antigens in primary and secondary recurrent spontaneous abortions. *Am J Obstet Gynecol* 163:178-188, 1990.

374. Takakuwa K, Kanazawa K, Takeuchi S: Production of blocking antibodies by vaccination with husband's lymphocytes in unexplained recurrent aborters: the role in successful pregnancy. *Am J Reprod Immunol Microbiol* 10:1-9, 1986.
375. Vanoli M, Fabio G, Bonara P, Eisera N, Pardi G, Acaia B, Smeraldi RS: Histocompatibility in Italian couples with recurrent spontaneous abortions of unknown origin and with normal fertility. *Tissue Antigens* 26:227-233, 1985.
376. Taylor CG, Faulk WP, McIntyre JA: Prevention of recurrent spontaneous abortions by leukocyte transfusions. *J R Soc Med* 78:623-627, 1985.
377. Reznikoff-Etievant MF, Edelman P, Muller JY, Pinon F, Sureau C: HLA-DR locus and maternal-foetal relation. *Tissue Antigens* 24:30-34, 1984.
378. Schacter B, Weitkamp LR, Johnson WE: Parental HLA compatibility, fetal wastage and neural tube defects: evidence for a T/t-like locus in humans. *Am J Hum Genet* 36:1082-1091, 1984.
379. Ho HN, Yang YS, Hsieh RP, Lin HR, Chen SU, Chen HF, Huang SC, Lee TY, Gill TJ, III: Sharing of human leukocyte antigens in couples with unexplained infertility affects the success of in vitro fertilization and tubal embryo transfer. *Am J Obstet Gynecol* 170:63-71, 1994.
380. Saravelos SH, Li TC: Unexplained recurrent miscarriage: how can we explain it? *Hum Reprod* 27:1882-1886, 2012.
381. Abbas A, Javed S, Agrawal S: Transcriptional status of HLA-G at the maternal-fetal interface in recurrent spontaneous abortion. *Int J Gynaecol Obstet* 93:148-149, 2006.
382. Patel RN, Quack KC, Hill JA, Schust DJ: Expression of membrane-bound HLA-G at the maternal-fetal interface is not associated with pregnancy maintenance among patients with idiopathic recurrent pregnancy loss. *Mol Hum Reprod* 9:551-557, 2003.
383. Emmer PM, Steegers EA, Kerstens HM, Bulten J, Nelen WL, Boer K, Joosten I: Altered phenotype of HLA-G expressing trophoblast and decidual natural killer cells in pathological pregnancies. *Hum Reprod* 17:1072-1080, 2002.
384. Strong RK, Holmes MA, Li P, Braun L, Lee N, Geraghty DE: HLA-E allelic variants. Correlating differential expression, peptide affinities, crystal structures, and thermal stabilities. *J Biol Chem* 278:5082-5090, 2003.
385. Bhalla A, Stone PR, Liddell HS, Zanderigo A, Chamley LW: Comparison of the expression of human leukocyte antigen (HLA)-G and HLA-E in women with normal pregnancy and those with recurrent miscarriage. *Reproduction* 131:583-589, 2006.
386. Castelli EC, Mendes-Junior CT, Deghaide NH, de Albuquerque RS, Muniz YC, Simoes RT, Carosella ED, Moreau P, Donadi EA: The genetic structure of 3'untranslated region of the HLA-G gene: polymorphisms and haplotypes. *Genes Immun* 11:134-141, 2010.
387. Ober C, Hyslop T, Elias S, Weitkamp LR, Hauck WW: Human leukocyte antigen matching and fetal loss: results of a 10 year prospective study. *Hum Reprod* 13:33-38, 1998.
388. Lagaay EL, Hennemann PH, Ruiszonetal M: Effect of one-HLA-DR-antigen-matched and completely HLA-DR-mismatched blood transfusion survival of heart and kidney allografts. *N England J Med* 321:701, 1989.
389. Lazda VA, Pollak R, Mozes MF, Barber PL, Jonasson O: Evidence that HLA class II disparity is required for the induction of renal allograft enhancement by donor-specific blood transfusions in man. *Transplantation* 49:1084-1087, 1990.
390. Claas FH, Roelen DL, van Rood JJ, Brand A: Modulation of the alloimmune response by blood transfusions. *Transfus Clin Biol* 8:315-317, 2001.
391. Santos MA, Kuijk EW, Macklon NS: The impact of ovarian stimulation for IVF on the developing embryo. *Reproduction* 139:23-34, 2010.
392. Boomsma CM, Macklon NS: What can the clinician do to improve implantation? *Reprod Biomed Online* 13:845-855, 2006.
393. Jenkins C, Roberts J, Wilson R, MacLean MA, Shilito J, Walker JJ: Evidence of a T(H) 1 type response associated with recurrent miscarriage. *Fertil Steril* 73:1206-1208, 2000.

394. Scherjon S, Lashley L, van der Hoorn ML, Claas F: Fetus specific T cell modulation during fertilization, implantation and pregnancy. *Placenta* 32 Suppl 4:S291-S297, 2011.
395. Moldenhauer LM, Diener KR, Thring DM, Brown MP, Hayball JD, Robertson SA: Cross-presentation of male seminal fluid antigens elicits T cell activation to initiate the female immune response to pregnancy. *J Immunol* 182:8080-8093, 2009.
396. Kwak-Kim JY, Chung-Bang HS, Ng SC, Ntrivalas EI, Mangubat CP, Beaman KD, Beer AE, Gilman-Sachs A: Increased T helper 1 cytokine responses by circulating T cells are present in women with recurrent pregnancy losses and in infertile women with multiple implantation failures after IVF. *Hum Reprod* 18:767-773, 2003.
397. Kalu E, Bhaskaran S, Thum MY, Vishwanatha R, Croucher C, Sherriff E, Ford B, Bansal AS: Serial estimation of Th1:Th2 cytokines profile in women undergoing in-vitro fertilization-embryo transfer. *Am J Reprod Immunol* 59:206-211, 2008.
398. Ng SC, Gilman-Sachs A, Thaker P, Beaman KD, Beer AE, Kwak-Kim J: Expression of intracellular Th1 and Th2 cytokines in women with recurrent spontaneous abortion, implantation failures after IVF/ET or normal pregnancy. *Am J Reprod Immunol* 48:77-86, 2002.
399. Chernyshov VP, Sudoma IO, Donskoi BV, Kostyuchyk AA, Masliy YV: Elevated NK cell cytotoxicity, CD158a expression in NK cells and activated T lymphocytes in peripheral blood of women with IVF failures. *Am J Reprod Immunol* 64:58-67, 2010.
400. Yang KM, Ntrivalas E, Cho HJ, Kim NY, Beaman K, Gilman-Sachs A, Kwak-Kim J: Women with multiple implantation failures and recurrent pregnancy losses have increased peripheral blood T cell activation. *Am J Reprod Immunol* 63:370-378, 2010.
401. Jin LP, Chen QY, Zhang T, Guo PF, Li DJ: The CD4+CD25 bright regulatory T cells and CTLA-4 expression in peripheral and decidual lymphocytes are down-regulated in human miscarriage. *Clin Immunol* 133:402-410, 2009.
402. Mei S, Tan J, Chen H, Chen Y, Zhang J: Changes of CD4+CD25high regulatory T cells and FOXP3 expression in unexplained recurrent spontaneous abortion patients. *Fertil Steril* 94:2244-2247, 2010.
403. Shima T, Sasaki Y, Itoh M, Nakashima A, Ishii N, Sugamura K, Saito S: Regulatory T cells are necessary for implantation and maintenance of early pregnancy but not late pregnancy in allogeneic mice. *J Reprod Immunol* 85:121-129, 2010.
404. Zhou J, Wang Z, Zhao X, Wang J, Sun H, Hu Y: An Increase of Treg Cells in the Peripheral Blood is Associated with a Better In Vitro Fertilization Treatment Outcome. *Am J Reprod Immunol* 68:100-106, 2012.
405. Beer AE, Kwak JY, Ruiz JE: Immunophenotypic profiles of peripheral blood lymphocytes in women with recurrent pregnancy losses and in infertile women with multiple failed in vitro fertilization cycles. *Am J Reprod Immunol* 35:376-382, 1996.
406. Kling C, Schmutzler A, Wilke G, Hedderich J, Kabelitz D: Two-year outcome after recurrent implantation failure: prognostic factors and additional interventions. *Arch Gynecol Obstet* 278:135-142, 2008.
407. Porter TF, LaCoursiere Y, Scott JR: Immunotherapy for recurrent miscarriage. *Cochrane Database Syst Rev* CD000112, 2006.
408. Chaouat G, Ledee-bataille N, Dubanchet S, Zourbas S, Sandra O, Martal J: TH1/TH2 paradigm in pregnancy: paradigm lost? Cytokines in pregnancy/early abortion: reexamining the TH1/TH2 paradigm. *Int Arch Allergy Immunol* 134:93-119, 2004.
409. Inagaki N, Stern C, McBain J, Lopata A, Kornman L, Wilkinson D: Analysis of intra-uterine cytokine concentration and matrix-metalloproteinase activity in women with recurrent failed embryo transfer. *Hum Reprod* 18:608-615, 2003.
410. Guerin LR, Moldenhauer LM, Prins JR, Bromfield JJ, Hayball JD, Robertson SA: Seminal fluid regulates accumulation of FOXP3+ regulatory T cells in the preimplantation mouse uterus through expanding the FOXP3+ cell pool and CCL19-mediated recruitment. *Biol Reprod* 85:397-408, 2011.

411. Robertson SA, Prins JR, Sharkey DJ, Moldenhauer LM: Seminal fluid and the generation of regulatory T cells for embryo implantation. *Am J Reprod Immunol* 69:315-330, 2013.
412. Bao SH, Wang XP, De LQ, Wang WJ, Yin GJ, Qiu LH: Decidual CD4+CD25+CD127dim/- regulatory T cells in patients with unexplained recurrent spontaneous miscarriage. *Eur J Obstet Gynecol Reprod Biol* 155:94-98, 2011.
413. Jasper MJ, Tremellen KP, Robertson SA: Primary unexplained infertility is associated with reduced expression of the T-regulatory cell transcription factor Foxp3 in endometrial tissue. *Mol Hum Reprod* 12:301-308, 2006.
414. Lu Y, Zhang F, Zhang Y, Zeng B, Hu L, Liao A: Quantitative reduction of peripheral CD4+ CD25+ FOXP3+ regulatory T cells in reproductive failure after artificial insemination by donor sperm. *Am J Reprod Immunol* 69:188-193, 2013.
415. Tai P, Wang J, Jin H, Song X, Yan J, Kang Y, Zhao L, An X, Du X, Chen X, Wang S, Xia G, Wang B: Induction of regulatory T cells by physiological level estrogen. *J Cell Physiol* 214:456-464, 2008.
416. Mao G, Wang J, Kang Y, Tai P, Wen J, Zou Q, Li G, Ouyang H, Xia G, Wang B: Progesterone increases systemic and local uterine proportions of CD4+CD25+ Treg cells during midterm pregnancy in mice. *Endocrinology* 151:5477-5488, 2010.
417. Leber A, Teles A, Zenclussen AC: Regulatory T cells and their role in pregnancy. *Am J Reprod Immunol* 63:445-459, 2010.
418. Thornton AM, Shevach EM: Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific. *J Immunol* 164:183-190, 2000.
419. Scheffold A, Huhn J, Hofer T: Regulation of CD4+CD25+ regulatory T cell activity: it takes (IL-) two to tango. *Eur J Immunol* 35:1336-1341, 2005.
420. Terasaki PI: Humoral theory of transplantation. *Am J Transplant* 3:665-673, 2003.
421. Lorenz M, Regele H, Schillinger M, Exner M, Rasoul-Rockenschaub S, Wahrmann M, Kletzmayer J, Silberhumer G, Horl WH, Bohmig GA: Risk factors for capillary C4d deposition in kidney allografts: evaluation of a large study cohort. *Transplantation* 78:447-452, 2004.
422. Gorczynski RM, Hadidi S, Yu G, Clark DA: The same immunoregulatory molecules contribute to successful pregnancy and transplantation. *Am J Reprod Immunol* 48:18-26, 2002.
423. Pirenne J, Kitade H, Kawai M, Koshiba T, Van DB, Mathieu C, Waer M: Regulatory cells, TH1/TH2 unbalance, and antibody-induced chronic rejection in operational tolerance induced by donor-specific blood transfusion. *Transplantation* 79:S25-S27, 2005.
424. Choudhury SR, Knapp LA: Human reproductive failure II: immunogenetic and interacting factors. *Hum Reprod Update* 7:135-160, 2001.
425. Tafuri A, Alferink J, Moller P, Hammerling GJ, Arnold B: T cell awareness of paternal alloantigens during pregnancy. *Science* 270:630-633, 1995.
426. Khosrotehrani K, Johnson KL, Lau J, Dupuy A, Cha DH, Bianchi DW: The influence of fetal loss on the presence of fetal cell microchimerism: a systematic review. *Arthritis Rheum* 48:3237-3241, 2003.
427. Khosrotehrani K, Johnson KL, Cha DH, Salomon RN, Bianchi DW: Transfer of fetal cells with multilineage potential to maternal tissue. *JAMA* 292:75-80, 2004.
428. Lashley LE, van der Hoorn ML, Haasnoot GW, Roelen DL, Claas FH: Uncomplicated oocyte donation pregnancies are associated with a higher incidence of human leukocyte antigen alloantibodies. *Hum Immunol* 75:555-560, 2014.
429. Pandian Z, Templeton A, Serour G, Bhattacharya S: Number of embryos for transfer after IVF and ICSI: a Cochrane review. *Hum Reprod* 20:2681-2687, 2005.
430. Ombelet W, Martens G, De SP, Gerris J, Bosmans E, Ruysinck G, Defoort P, Molenberghs G, Gyselaers W: Perinatal outcome of 12,021 singleton and 3108 twin births after non-IVF-assisted reproduction: a cohort study. *Hum Reprod* 21:1025-1032, 2006.
431. Salihu HM, Aliyu MH, Rouse DJ, Kirby RS, Alexander GR: Potentially preventable excess mortality among higher-order multiples. *Obstet Gynecol* 102:679-684, 2003.

432. Ebner T, Moser M, Sommergruber M, Tews G: Selection based on morphological assessment of oocytes and embryos at different stages of preimplantation development: a review. *Hum Reprod Update* 9:251-262, 2003.
433. Artini PG, Valentino V, Cela V, Cristello F, Vite A, Genazzani AR: A randomized control comparison study of culture media (HTF versus P1) for human in vitro fertilization. *Eur J Obstet Gynecol Reprod Biol* 116:196-200, 2004.
434. Gott AL, Hardy K, Winston RM, Leese HJ: Non-invasive measurement of pyruvate and glucose uptake and lactate production by single human preimplantation embryos. *Hum Reprod* 5:104-108, 1990.
435. Thompson JG, Mitchell M, Kind KL: Embryo culture and long-term consequences. *Reprod Fertil Dev* 19:43-52, 2007.
436. Hemmings R, Langlais J, Falcone T, Granger L, Miron P, Guyda H: Human embryos produce transforming growth factors alpha activity and insulin-like growth factors II. *Fertil Steril* 58:101-104, 1992.
437. O'Neill C, Gidley-Baird AA, Pike IL, Saunders DM: Use of a bioassay for embryo-derived platelet-activating factor as a means of assessing quality and pregnancy potential of human embryos. *Fertil Steril* 47:969-975, 1987.
438. Hviid TV: HLA-G in human reproduction: aspects of genetics, function and pregnancy complications. *Hum Reprod Update* 12:209-232, 2006.
439. Dey SK, Lim H, Das SK, Reese J, Paria BC, Daikoku T, Wang H: Molecular cues to implantation. *Endocr Rev* 25:341-373, 2004.
440. Ledee-bataille N, Bonnet-Chea K, Hosny G, Dubanchet S, Frydman R, Chaouat G: Role of the endometrial tripod interleukin-18, -15, and -12 in inadequate uterine receptivity in patients with a history of repeated in vitro fertilization-embryo transfer failure. *Fertil Steril* 83:598-605, 2005.
441. Abate V, De CR, Cali A, Stinchi A: Endometrial biopsy at the time of embryo transfer: correlation of histological diagnosis with therapy and pregnancy rate. *J In Vitro Fert Embryo Transf* 4:173-176, 1987.
442. Ubaldi F, Bourgain C, Tournaye H, Smits J, Van SA, Devroey P: Endometrial evaluation by aspiration biopsy on the day of oocyte retrieval in the embryo transfer cycles in patients with serum progesterone rise during the follicular phase. *Fertil Steril* 67:521-526, 1997.
443. Tang AW, Alfirevic Z, Quenby S: Natural killer cells and pregnancy outcomes in women with recurrent miscarriage and infertility: a systematic review. *Hum Reprod* 26:1971-1980, 2011.
444. van der Gaast MH, Beier-Hellwig K, Fauser BC, Beier HM, Macklon NS: Endometrial secretion aspiration prior to embryo transfer does not reduce implantation rates. *Reprod Biomed Online* 7:105-109, 2003.
445. van der Molen RG, Schutten JH, van CB, ter MM, Donckers J, Scholten RR, van der Heijden OW, Spaanderman ME, Joosten I: Menstrual blood closely resembles the uterine immune micro-environment and is clearly distinct from peripheral blood. *Hum Reprod* 29:303-314, 2014.
446. Sabbaj S, Hel Z, Richter HE, Mestecky J, Goepfert PA: Menstrual blood as a potential source of endometrial derived CD3+ T cells. *PLoS One* 6:e28894, 2011.
447. Quenby S, Vince G, Farquharson R, Aplin J: Recurrent miscarriage: a defect in nature's quality control? *Hum Reprod* 17:1959-1963, 2002.
448. Teklenburg G, Salker M, Molokhia M, Lavery S, Trew G, Aojanepong T, Mardon HJ, Lokugamage AU, Rai R, Landles C, Roelen BA, Quenby S, Kuijk EW, Kavelaars A, Heijnen CJ, Regan L, Brosens JJ, Macklon NS: Natural selection of human embryos: decidualizing endometrial stromal cells serve as sensors of embryo quality upon implantation. *PLoS One* 5:e10258, 2010.
449. Zoet YM, Eijssink C, Kardol MJ, Franke-van Dijk ME, Wilson GL, de PR, Mickelson E, Heemskerk M, van den Elsen PJ, Claas FH, Mulder A, Doxiadis II: The single antigen expressing lines (SALs) concept: an excellent tool for screening for HLA-specific antibodies. *Hum Immunol* 66:519-525, 2005.

450. Martin L, Guignier F, Mousson C, Rageot D, Justrabo E, Rifle G: Detection of donor-specific anti-HLA antibodies with flow cytometry in eluates and sera from renal transplant recipients with chronic allograft nephropathy. *Transplantation* 76:395-400, 2003.
451. Mohanakumar T, Waldrep JC, Phibbs M, Mendez-Picon G, Kaplan AM, Lee HM: Serological characterization of antibodies eluted from chronically rejected human renal allografts. *Transplantation* 32:61-66, 1981.
452. Ball B, Mousson C, Ratignier C, Guignier F, Glotz D, Rifle G: Antibodies to vascular endothelial cells in chronic rejection of renal allografts. *Transplant Proc* 32:353-354, 2000.
453. Sumitran-Holgersson S: Relevance of MICA and other non-HLA antibodies in clinical transplantation. *Curr Opin Immunol* 20:607-613, 2008.
454. Ohe H, Uchida Y, Yoshizawa A, Hirao H, Taniguchi M, Maruya E, Yurugi K, Hishida R, Maekawa T, Uemoto S, Terasaki PI: Association of Anti-Human Leukocyte Antigen and Anti-Angiotensin II Type 1 Receptor Antibodies With Liver Allograft Fibrosis After Immunosuppression Withdrawal. *Transplantation* 2014.
455. Rogenhofer N, Ochsenkuhn R, von S, V, Assef RB, Thaler CJ: Antitrophoblast antibodies are associated with recurrent miscarriages. *Fertil Steril* 97:361-366, 2012.
456. Robertson SA, Sharkey DJ: The role of semen in induction of maternal immune tolerance to pregnancy. *Semin Immunol* 13:243-254, 2001.
457. Robertson SA: Seminal plasma and male factor signalling in the female reproductive tract. *Cell Tissue Res* 322:43-52, 2005.
458. Koelman CA, Coumans AB, Nijman HW, Doxiadis II, Dekker GA, Claas FH: Correlation between oral sex and a low incidence of preeclampsia: a role for soluble HLA in seminal fluid? *J Reprod Immunol* 46:155-166, 2000.
459. Kelly RW: Immunosuppressive mechanisms in semen: implications for contraception. *Hum Reprod* 10:1686-1693, 1995.
460. Dekker G, Robillard PY, Roberts C: The etiology of preeclampsia: the role of the father. *J Reprod Immunol* 89:126-132, 2011.
461. Coulam CB, Stern JJ: Effect of seminal plasma on implantation rates. *Early Pregnancy* 1:33-36, 1995.
462. Tremellen KP, Valbuena D, Landeras J, Ballesteros A, Martinez J, Mendoza S, Norman RJ, Robertson SA, Simon C: The effect of intercourse on pregnancy rates during assisted human reproduction. *Hum Reprod* 15:2653-2658, 2000.
463. Boomsma CM, Keay SD, Macklon NS: Peri-implantation glucocorticoid administration for assisted reproductive technology cycles. *Cochrane Database Syst Rev* 6:CD005996, 2012.
464. Ubaldi F, Rienzi L, Ferrero S, Anniballo R, Iacobelli M, Cobellis L, Greco E: Low dose prednisolone administration in routine ICSI patients does not improve pregnancy and implantation rates. *Hum Reprod* 17:1544-1547, 2002.
465. RCOG. Immunological testing and interventions for reproductive failure. 2008. Scientific Impact Paper No 5.
466. Lagaaij EL, Hennemann IP, Ruigrok M, de Haan MW, Persijn GG, Termijtelen A, Hendricks GF, Weimar W, Claas FH, van Rood JJ: Effect of one-HLA-DR-antigen-matched and completely HLA-DR-mismatched blood transfusions on survival of heart and kidney allografts. *N Engl J Med* 321:701-705, 1989.
467. van der Mast BJ, Balk AH: Effect of HLA-DR-shared blood transfusion on the clinical outcome of heart transplantation. *Transplantation* 63:1514-1519, 1997.
468. Waanders MM, Roelen DL, Brand A, Claas FH: The putative mechanism of the immunomodulating effect of HLA-DR shared allogeneic blood transfusions on the alloimmune response. *Transfus Med Rev* 19:281-287, 2005.
469. Hutton B, Sharma R, Fergusson D, Tinmouth A, Hebert P, Jamieson J, Walker M: Use of intravenous immunoglobulin for treatment of recurrent miscarriage: a systematic review. *BJOG* 114:134-142, 2007.

470. Saito S, Fukunaga R, Ichijo M, Nagata S: Expression of granulocyte colony-stimulating factor and its receptor at the fetomaternal interface in murine and human pregnancy. *Growth Factors* 10:135-143, 1994.
471. Ziebe S, Loft A, Povlsen BB, Erb K, Agerholm I, Aasted M, Gabrielsen A, Hnida C, Zobel DP, Munding B, Bendz SH, Robertson SA: A randomized clinical trial to evaluate the effect of granulocyte-macrophage colony-stimulating factor (GM-CSF) in embryo culture medium for in vitro fertilization. *Fertil Steril* 99:1600-1609, 2013.
472. Santjohanser C, Knieper C, Franz C, Hirv K, Meri O, Schleyer M, Wurfel W, Toth B: Granulocyte-colony stimulating factor as treatment option in patients with recurrent miscarriage. *Arch Immunol Ther Exp (Warsz)* 61:159-164, 2013.
473. Scarpellini F, Sbracia M: Use of granulocyte colony-stimulating factor for the treatment of unexplained recurrent miscarriage: a randomised controlled trial. *Hum Reprod* 24:2703-2708, 2009.
474. Schlahsa L, Jaimes Y, Blasczyk R, Figueiredo C: Granulocyte-colony-stimulatory factor: a strong inhibitor of natural killer cell function. *Transfusion* 51:293-305, 2011.
475. Winger EE, Reed JL: Treatment with tumor necrosis factor inhibitors and intravenous immunoglobulin improves live birth rates in women with recurrent spontaneous abortion. *Am J Reprod Immunol* 60:8-16, 2008.
476. Jerzak M, Ohams M, Gorski A, Baranowski W: Etanercept immunotherapy in women with a history of recurrent reproductive failure. *Ginekol Pol* 83:260-264, 2012.

Curriculum Vitae

Lisa Lashley was born on the 1st of December 1980 in Dordrecht, the Netherlands. She graduated in 1998 from secondary school at the Gymnasium Camphusianum in Gorinchem. In the same year, she started with Bio-pharmaceutical Sciences at Leiden, a study focusing on research-oriented training in pharmaceutical sciences and medicine development. She graduated in 2003 and started in the third year of the curriculum of Medicine at the Leiden University. During her study she worked at the Center for Human Drug Research (CHDR) as research assistant and at the emergency department of the Leiden University Medical Center (LUMC). In 2007 she graduated and worked as a physician at the Obstetrics and Gynecology department of the Haga hospital in the Hague and of the LUMC. She became involved in the research on immunology in pregnancy at the Reproductive Immunology laboratory, LUMC, under the guidance of Prof. dr. F.H.J. Claas. She was assigned a grant from ZonMW, NWO, which gave her the opportunity to start a research project, resulting in the current thesis.

In 2010 she started her residency training in Obstetrics and Gynecology at the Haga hospital (head: dr. B.W.J. Hellebrekers) and after two years of research, she continued her training at the LUMC (head: Prof. dr. J.M.M. van Lith).

Lisa lives together in the Hague with Jaap Vestjens and their daughter Lotte.

List of publications

E.E.L.O. Lashley, L.A.J. van der Westerlaken, G.W. Haasnoot, J.J.M. Drabbels, M.J. Spruyt-Gerittse, S.A. Scherjon and F.H.J. Claas. Maternal HLA-C2 and 14bp insertion in HLA-G is associated with recurrent implantation failure after *in vitro* fertilization treatment. Tissue Antigens 2014; 84(6):536-44

E.E.L.O. Lashley, M.L.P. van der Hoorn, G.W. Haasnoot, D.L. Roelen, F.H.J. Claas. Uncomplicated oocyte donation pregnancies are associated with a higher incidence of human leukocyte antigen alloantibodies. Hum Immunology 2014; 75(6):555-60

E.E.L.O. Lashley, T. Meuleman, F.H.J. Claas. Beneficial or harmful effect of anti paternal human leukocyte antibodies on pregnancy outcome? A systematic review and meta-analysis. Am J Repr Imm 2013 ;70(2):87-103

D.J. Piersma, **E.E.L.O. Lashley**, B.W.J. Hellebrekers. Uitblijvende menses na gebruik van vaginale kruiden. NTOG 2012, Vol 125, 305-306

D.J. Piersma, **E.E.L.O. Lashley**, B.W.J. Hellebrekers. Uitblijvende menstruatie na gebruik van vaginale kruiden. Nederlands Tijdschrift Tegen Kwakzalverij 2012

E.E.L.O. Lashley, M.L.P. van der Hoorn, B.J. van der Mast, T. Tilburgs, N. van der Lee, C. van der Keur, E. van Beelen, D.L. Roelen, F.H.J. Claas, S.A. Scherjon. Changes in cytokine production and composition of peripheral blood leukocytes during pregnancy are not associated with a difference in the proliferative immune response to the fetus. Hum Imm. 2011 Oct;72(10):805-11. Epub 2011 Jun 12

S.A. Scherjon, **E.E.L.O Lashley**, M.L.P van der Hoorn, F.H.J. Claas. Fetus specific T cell modulation during fertilization, implantation and pregnancy. Placenta. 2011 Oct;32 Suppl 4:S291-7. Epub 2011 May 17

M.L.P. van der Hoorn, **E.E.L.O. Lashley**, D.W. Bianchi, F.H.J. Claas, C.M.C. Schonkeren, S.A. Scherjon. Clinical and immunologic aspects of egg donation pregnancies: a systematic review. Hum Reprod Update. 2010;16(6):704-12

E.E.L.O. Lashley, M.L.P. van der Hoorn, S.A. Scherjon. Pre-eclampsie als complicatie bij eiceldonatie, een ander pathofysiologisch mechanisme? Ned Tijdschr Geneesk. 2010;154:A1982.

M. Knoester, **L.E. Lashley**, E. Wessels, D. Oepkes, E.J. Kuijper. First report of *Atopobium vaginae* bacteremia with fetal loss after chorionic villus sampling. *J Clin Microbiol.* 2011 Apr;49(4):1684-6. Epub 2011 Feb 2.

H.F. Wunderink, **E.E. Lashley**, M.I. van Poelgeest, K.N. Gaarenstroom, E.C. Claas, E.J. Kuijper. Pelvic actinomycosis-like disease due to *Propionibacterium propionicum* after hysteroscopic removal of an intrauterine device. *J Clin Microbiol.* 2011 Jan;49(1):466-8. Epub 2010 Nov 10

E.M.G. van Esch, **E.E. Lashley**, C.D. de Kroon, The value of hysteroscopy in the diagnostic approach of a rudimentary horn pregnancy, nov 2010 *BMJ Case Reports*

E.E.L.O. Lashley, A.H. Feitsma. Een vrouw met een vulvaire zwelling, *Ned Tijdschr Geneesk.* 2009;153:A115

E.E.L.O. Lashley, H. van Houten, H.P. Ottervanger. Primaire hyperparathyreoïdie als oorzaak van hyperemesis gravidarum, *Ned Tijdschr Geneesk.* 2009;153(17)

E.E.L.O. Lashley, M.I. Versteegh, R. Smithuis, H. Dik. Geen pulmonaal infiltraat, maar een longsekwester bij een 45-jarige vrouw, *Ned Tijdschr Geneesk.* 2006 Oct 21;150(42):2324-9

A.S. Janssens, **E.E. Lashley**, C.J. Out, R. Willemze, S. Pavel, S.R. de Gruijl. UVB-induced leucocyte trafficking in the epidermis of photosensitive lupus erythematosus patients: normal depletion of Langerhans cells, *Exp Dermatol.* 2005 Feb;14(2):138-42

Y.Y. Grams, S. Alarukka, **L. Lashley**, J. Caussin, L. Whitehead, J.A. Bouwstra. Permeant lipophilicity and vehicle composition influence accumulation of dyes in hair follicles of human skin. *Eur J Pharm Sci.* 2003 Apr;18(5):329-36

Abbreviations

3p	third party
APC	antigen presenting cell
ART	assisted reproductive techniques
BCR	B cell receptor
CD	cluster of differentiation
CDC	complement dependent cytotoxicity
CPM	counts per minute
DC	dendritic cell
ELISA	enzyme linked immunosorbent assay
EVT	extravillous trophoblasts
FACS	fluorescent activated cell sorting
HELLP	hemolysis elevated liver enzymes, low platelets
HLA	human leukocyte antigen
ICSI	intra cytoplasmatic sperm injection
IDO	indolamine 2,3-dioxygenase
IFN- γ	interferon- γ
IL	interleukin
IVF	in vitro fertilization
KIR	killer immuno-globulin like receptor
MFI	median fluorescence intensity
MHC	major histocompatibility complex
MLC	mixed lymphocyte culture
MLR	mixed lymphocyte reaction
NK	natural killer
OD	oocyte donation
PBL	peripheral blood leukocyte
PBMC	peripheral blood mononuclear cell
PE	preeclampsia
PHA	phytohaemagglutinin
RIF	recurrent implantation failure
RSM	recurrent spontaneous miscarriages
SAB	single antigen beads
SI	stimulation index
sIVF	success after one IVF or ICSI treatment
SP	spontaneously conceived pregnancy
SUI	suppression index
TCR	T cell receptor
TGF	transforming growth factor

Th	T helper
TNF	tumor necrosis factor
Treg	regulatory T cell
UCB	umbilical cord blood

Acknowledgements

De afgelopen jaren heb ik van velen hulp en steun gekregen tijdens de vorming van dit proefschrift. Enkele van deze mensen wil ik specifiek bedanken:

Frans, ik had geen betere begeleiding kunnen wensen. Je weet de perfecte balans te creëren tussen vrijheid geven en in de juiste richting sturen, gecombineerd met een hoop humor en menselijkheid. Dank voor je vertrouwen en voor je positiviteit.

Jan, dank voor je interesse en steun bij het tot stand komen van dit proefschrift. En natuurlijk voor de tip om voor de ZonMW stipendium in te sturen!

Lieve paranimfen Marie-Louise en Tess, ik heb de afgelopen jaren met zoveel plezier gewerkt en daar zijn jullie voor een groot deel verantwoordelijk voor. Dank voor een overgetelijke tijd in het 'kippenhok'!

Sicco, jouw enthousiasme haalde me over me in dit onderwerp te storten. Dank voor jouw, weliswaar korte, maar 'PRIMA' begeleiding!

Dames van het lab Reproductieve Immunologie: Carin, Go, Els, Dienne, Angela en sinds kort, Moniek, dank voor al jullie gezelligheid en interesse. Carin, Go en Els, dank voor al het werk wat jullie voor mij hebben gedaan en het geduld wat jullie met me hebben gehad.

Groot dank ook aan alle medewerkers van de afdeling IHB, met name iedereen van typerings- en screeningslab, Simone, Geert, Yvonne, Jos, Dave, Michael, Sebastiaan, Niels, Heleen, Monique, Gonca en Marijke.

Lieve studenten Yara, Rowena, Kaveri en Soraya, dank voor alles wat ik van jullie heb geleerd.

Anouk, Gladys en Ivanka, dank voor de secretariële ondersteuning en de gezelligheid tussendoor.

Dank aan alle vrouwen en mannen die materiaal hebben afgestaan en aan iedereen die meegeholpen heeft met het verzamelen van dit materiaal: Marjolein en Clara, Tineke Goekoop, Bets en Anita, medewerkers gynaecologie/verloskunde LUMC, medewerkers gynaecologie/verloskunde Bronovo Ziekenhuis, met name Kim Boers en Cas Holleboom, en medewerkers gynaecologie/verloskunde Haga Ziekenhuis.

Mede-onderzoekers Ada, Aletta, Claartje, Claire, Dacia, Edith, Ellen Hoekman, Ellen Stelloo, Femke, Fenna, Helene, Inge, Jolijn, Joost, Linda, Lucas, Marlies Penning, Marlies Schrevel, Mathijs, Peggy, Sanne, Sara, Sharon, Simone, Suus en Vivian: dank voor alle goede input en gezelligheid!

Lieve Joke, dank voor je fantastische humor en nuchterheid, ik hoop op nog veel mooie momenten, samen met Jasper, Roos en Pien.

Lieve Anne, Karin, Edith, Rosa en Miriam. Wat is het heerlijk om met jullie nog steeds, inmiddels wel iets meer volwassen, grappen te maken. Meer boer!

Lieve schoonfamilie, dank voor jullie bijzondere betrokkenheid en de heerlijke ontspannen weekendjes en vakanties.

Lieve Mamma, Frank, Saar, Faab en Morgan, jullie zijn mijn thuishaven. Dank voor alles en nog meer!

Pap, ik weet dat je deze dag voor geen goud had willen missen. Ik hoop dat ik je er ooit uitgebreid verslag van mag doen.

Lieve Jaap, mijn meest geliefde en meest kritische reviewer; dank voor je nimmer aflatende interesse en steun.

Mooiste HLA match Lotte, je hebt me nu al zoveel geleerd, ik kan niet wachten op de toekomst!